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Drug membrane interactions play an important role in drug transport, distribution, 
accumulation, efficacy, and resistance. Thus, the measure of drug-membrane partitioning, 
expressed here as lipophilicity, is one of the most important physicochemical parameters in 
predicting and interpreting membrane permeability. The partitioning of the drug depends on 
both the properties of the membrane and the structural and physicochemical properties of the 
drug. As most drugs are administered via the oral route, the drug has to overcome the 
epithelial barriers in the stomach and intestinal tract. Therefore, one of the most important 
factors influencing oral absorption is the permeability of the monolayer of the intestinal 
epithelial cells lining the gastrointestinal tract. As well, the understanding of the mechanism 
and the factors influencing the drug release from the drug delivery system and transfer to the 
site of the action to be up taken by the body cells is prerequisite for drug formulation. 
Thereby, the partitioning of structurally diverse compounds using different artificial 
membranes had been investigated. In addition, the factors influencing liposomal formulation 
of a photosensitizing agent (Temoporfin; mTHPC) and the kinetics of transfer between donor 
liposomes (drug carrier) and acceptor liposomes (artificial membrane) using the radiolabeled 
analogue [14C]mTHPC were studied. Two different artificial membranes, immobilized 
artificial membrane (IAM.PC.DD2) and XBridgeTM Shield RP18, were chosen using reversed 
phase high performance liquid chromatography (RP-HPLC). The lipophilicity indices 
obtained from the two membranes were compared to lipophilicity index of n-octanol/water 
(log Poct). In terms of mTHPC transfer, to obtain a better insight into the dynamics of mTHPC 
transfer between membranes, an in vitro model was established. This in vitro model consists 
of drug incorporation into negatively or positively charged liposomes (donor) and neutral 
acceptor liposomes which allow the measurement of drug concentration in the acceptor 
liposomes. Separation of donor and acceptor liposomes of samples taken during the 
experiments was done by using a mini ion-exchange column. The parameters studied were 
total lipid content, temperature, charge of donor vesicles, and finally fatty acyl chain structure 
regarding the length and saturation of phospholipids in donor vesicles. 
 
The results showed significant correlations between the retention factor log kwIAM on 
IAM.PC.DD2 and log Poct or log D7.0 for neutral or structurally related compounds, implying 
that the retention mechanisms are same among neutral or structurally related compounds. The 
retention of the ionized compounds on IAM.PC.DD2 is controlled not only by lipophilicity, 
but also by extra-interactions, mainly electrostatic interactions between charged solutes and 
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phospholipids. For the solutes investigated on IAM.PC.DD2, positively charged compounds 
are more retained than negatively charged solutes.  
 
For the XbridgeTM shield RP18 phase, it yielded a lipophilicity index log Kw highly correlated 
with log Poct values for the whole set of compounds investigated. A linear solvation free-
energy relationships (LSERs) analysis showed that retention on the XbridgeTM shield RP18 
phase and partitioning in n-octanol/water are controlled by the same balance of structural 
properties, namely the Van der Waals volume (Vw), H-bond acceptor basicity (β) and 
dipolarity/polarizability (π*). The study showed that the XbridgeTM shield RP18 novel 
stationary phase overcomes the shortcomings of the silica-based stationary phases, whose 
application in lipophilicity measurements is limited to neutral and acidic compounds.  
 
With respect to mTHPC transfer between liposomal membranes, the obtained results are 
consistent with a first order kinetics in which the transfer may proceed through liposome 
collisions or through the aqueous phase. A corresponding theoretical model was presented 
which accounts for the detailed distribution of drug molecules in donor and acceptor 
liposomes and predicts the transfer rates as function of drug concentration and number of 
donor and acceptor liposomes. The experimentally observed transfer rates depended strongly 
on the temperature and comply with Arrhenius equation. Thermodynamics calculations 
indicated that the transfer process is entropically controlled. In terms of the charge of donor 
liposomes, positively charged liposomes showed transfer rate faster than negatively charged 
liposomes while the maximum amount transferred is almost the same. By investigation of the 
effect of acyl chain length and saturation of phospholipids of donor vesicles, a potential 
relationship between transfer rate and membrane rigidity was evident since the transfer rate 












Wechselwirkungen zwischen Arzneistoffen und Membranen spielen eine wichtige Rolle im 
Arzneistofftransport, sowie der Verteilung, Anreicherung im Gewebe und der Wirksamkeit. 
Folglich ist die Verteilung zwischen Arzneimittel und Membran, die hier als Lipophilie 
ausgedrückt wird, eine der wichtigsten physikochemischen Parameter beim Voraussagen und 
Interpretieren der Membranpermeabilität. Die Verteilung des Arzneistoffes hängt sowohl vom 
Aufbau der Membran als auch von strukturellen und physikochemischen Eigenschaften des 
Arzneistoffes ab. Da heutzutage die meisten Arzneitstoffe oral verabreicht werden, müssen 
diese die epithelialen Barrieren im Magen und Darmtrakt überwinden. Daher ist die 
Durchlässigkeit des Monolayers der Darmepithelzellen des Gastrointestinaltraktes einer der 
wichtigsten Faktoren, der die orale Aufnahme beeinflusst. Eine weitere wichtige 
Voraussetzung für eine effiziente Arzneistofffomulierung ist das Verständnis für die 
Mechanismen und Faktoren, die die Arzneistofffreisetzung vom Trägersystem, dessen 
Transfer zum Wirkort und die Aufnahme in Zellen beeinflussen. Hierfür wurde die Verteilung 
strukturell unterschiedlicher Verbindungen mittels des Einsatzes verschiedener künstlicher 
Membranen untersucht. Zusätzlich wurden Faktoren, die die liposomale Formulierung eines 
photosensiblen Stoffes (Temoporfin; mTHPC) und dessen Transferkinetik zwischen 
Donorliposomen (Arzneiträger) und Akzeptorliposomen (künstliche Membran) beeinflussen, 
untersucht. Die Experimente wurden mit dem radioaktiv markierten Analogon [14C]mTHPC 
durchgeführt. Zwei unterschiedliche künstliche Membranen, die immobilisierte künstliche 
Membran (IAM.PC.DD2) und XBridgeTM Shield RP18, wurden mittels Umkehrphasen- 
Hochleistungsflüssigkeitschromatografie (RP-HPLC) ausgewählt.  Die von den Membranen 
erhaltenen Lipophilie-Indizes, wurden mit dem lipophilie Index von n-Octanol/Wasser (log 
Poct) verglichen. Um einen besseren Einblick in die Dynamik des mTHPC Membrantransfers 
zu gewinnen, wurde ein in vitro Modell etabliert. Dieses in vitro Modell beinhaltet das Laden 
von Arzneistoffen in negativ oder positiv geladene Liposomen (Donor) und neutralen 
Akzeptorliposomen. Im Anschluß ist es möglich, die Arzneistoffkonzentration im 
Akzeptorliposom zu quantifizieren. Die Trennung der Donor und Akzeptorliposmen erfolgte 
über eine mini Ionenaustauschersäule. Zu den untersuchten Parametern gehörten der totale 
Lipidgehalt, Temperatur, Ladung der Donorvesikel, und schließlich die Struktur der 




Die Ergebnisse zeigten eine signifikante Korrelation zwischen dem Retentionsfaktor log 
kwIAM von IAM.PC.DD2 und log Poct oder log D7.0 für neutral oder strukturell verwandte 
Zusammensetzungen, was besagt, dass die Retentionsmechanismen bei neutralen oder 
strukturell verwandten Zusammensetzungen gleich sind. Die Retention von ionischen 
Zusammensetzungen auf IAM.PC.DD2 wird nicht nur durch deren Lipophilie, sondern auch 
durch zusätzliche Wechselwirkungen, beeinflusst. Es handelt sich hauptsächlich um 
elektrostatische Wechselwirkungen zwischen geladenen gelösten Stoffen und Phospholipiden. 
Unter den auf IAM.PC.DD2 geprüften Verbindungen, wurden positiv geladene 
Zusammensetzungen  stärker zurückgehalten  als negativ geladene.  
 
Für die XbridgeTM Shield RP18 Phase ergab sich ein Lipophilie-Index log Kw, der eine hohe 
Korrelation mit den log Poct Werten aller getesteten Verbindungen aufwies. Eine Lineare 
Freie-Energie-Beziehungs (LSERs) Analyse zeigte, dass die Retention auf der XbridgeTM 
Shield RP18 Phase und die Verteilung in n-Octanol/Wasser auf der selben Ausgewogenheit  
struktureller Eigenschaften basieren, im speziellen auf dem Van der Waals Volumen (Vw), 
der H-Brücken Akzeptorbasizität (β) und der Dipolarität/Polarisierbarkeit (π*). Die Tests 
haben gezeigt, dass die neue stationäre XbridgeTM Shield RP18 Phase die Mängel von auf 
Kieselgel basierenden stationären Phasen überwinden kann, die nur lipophilie Messungen von 
neutralen und sauren Verbindungen ermöglichen.  
 
Die erhaltenen Daten des mTHPC Transfers zwischen liposomalen Membranen zeigten, dass 
der Transfer einer Kinetik erster Ordnung folgt, und möglicherweise durch Zusammenstöße 
der Liposomen oder über die wässrige Phase erfolgt. Ein entsprechendes theoretisches Modell 
wurde präsentiert, welches die detaillierte Verteilung von Arzneistoffmolekülen in Donor und 
Akzeptorliposomen zeigt, und die Transferraten als Funktion von Arzneistoffkonzentration 
und der Anzahl von Donor und Akzeptorliposomen vorraussagen kann. Die experimentell 
ermittelten Transferraten waren stark temperaturabhängig und entsprachen der Arrhenius 
Gleichung. Thermodynamische Berechnungen haben gezeigt, dass der Übertragungsprozess 
entropisch kontrolliert ist. Bezüglich der Ladung der Donorliposomen, zeigten positiv 
geladene Liposomen eine schnellere Transferrate als negativ geladene Liposomen, während 
die maximal übertragene Menge fast dieselbe war. Durch Untersuchung der 
Kohlenwasserstoffkettenlänge und des Sättigungsgrades der Phospholipide der Donorvesikel 
konnte eine positive Korrelation zwischen der Übertragungsrate und der Membransteifigkeit 
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1.1 INTRODUCTION  
Concern in drug design has focussed mainly on the interaction of ligand molecules with 
proteins, in the form of specific receptors and enzymes. Membranes contain most of the target 
proteins, and it is supposed that the drugs display their action as a result of binding to the 
membrane-embedded proteins. The lipid part in membrane is well known to play a more 
passive role. However, there is increasing the opinion that the influence of drug-membrane 
interaction on drug activity and selectivity has been underestimated in the past. The so-called 
‘‘non-specific’’ interaction of drugs with membrane constituents in fact involves an 
interaction with specific phospholipids structures. Although the lipid layer is a dynamic fluid, 
it is highly organized. Interaction with the organised phospholipid structures can have a 
decisive influence on drug partitioning, orientation, conformation, and drug transfer between 
membranes as well. It also has an effect on the physicochemical properties and functioning of 
the membrane. Therefore, drug membrane interactions play an important role in drug 
transport, distribution, accumulation, efficacy, and resistance (1). In general, most of drugs 
reach their target organ via the blood circulation system. As a result, the drug molecules first 
have to pass through barrier membranes in the gastrointestinal tract to enter the circulation. 
The partitioning or the transfer of the drug depends on both the properties of the membrane 
and physicochemical properties of the drug. In addition, the majority of the drugs are 
administered by the oral route. So, the barrier the drug has to overcome in the stomach and 
intestinal tract is a monolayer epithelium. Therefore, the main factor influencing oral 
absorption is the permeability of the monolayer of the intestinal epithelial cells lining the 
gastrointestinal tract. As the active thransepithelial resorption is the exception rather than the 
rule, and as no watery pores exist in the intact mucosa, drugs must have certain lipophilic 
properties if they are to cross the epithelium of the intestine by passive diffusion, including 
paracellular and transcellular permeation. On the other hand, for the drug partitioning or 
release from the formula into the watery fluid of the stomach or intestine requires a certain 
degree of solubility in water. It is therefore accepted and very well known that the percentage 
absorbed in general follow a non-linear dependency with lipophilicity, normally being 
expressed as the n-octanol-water partition coefficient (log Poct) (2). Whereas molecular 
volume is the foremost determinant of whether a solute may cross the paracellular pathway 
(3, 4), lipophilicity gives indirect information on how likely that pathway is to play a 
significant role in bioavailability. In addition, lipophilicity may give indication about 
substrate-transporter interaction, either by local or global information on substrate 
hydrophobicity. The importance of drug lipophilicity determination (5, 6), however, is that it 
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directly influences the degree of membrane partitioning and hence passive membrane 
transport of solutes. In assessment of drug-membrane partitioning, lipophilicity is considered 
one of the most important physicochemical parameters in predicting and interpreting 
membrane permeability. The dependence of oral drug absorption on drug lipophilicity was 
demonstrated (7) and implicated an optimal range of partition coefficients for a chemical 
series (8). Later work, in which a model for intestinal absorption potential was derived, 
defined the critical physicochemical components for absorption as partition coefficient, 
fraction in non-ionised form at pH 6.5, and the dose-solubility ratio (9). The dependence of 
passive transport on lipophilicity has been also recognized by researchers investigating the 
permeation of the drugs through the blood-brain barrier (10-12). Moreover, numerous studies 
(13) of quantitative structure-permeability relationship (QSPR) have explicitly verified that 
lipophilicity, as related to membrane partitioning and hence passive transcellular diffusion, is 
a key parameter in predicting and interpreting permeability. In these studies, lipophilicity is 
often equated with the n-octanol/water partition coefficient (log Poct) (13). The partition 
coefficient (log Poct) in this solvent system (n-octanol/water) is traditionally accepted as an 
informative model of membrane partitioning (14). As a molecular parameter, lipophilicity 
encodes both polar and hydrophobic intermolecular forces. But when expressed by partition 
coefficients measured in traditional organic solvent/water systems, lipophilicity fails to 
encode some important recognition forces, most notably ionic bonds, which are of particular 
importance when modelling the interaction of ionized compounds with membranes. And in 
fact, a recent statistic found that 62.9 % of drugs are ionisable, of which 14.5 % are acids, 
67.6 % are bases, and 17.9 % are ampholytes of various types (13). So, any prediction of 
pharmacodynamic and pharmacokinetic properties of the drugs should take their ionization 
into account since the majority of drugs are ionisable. Therefore, at a pH value where the 
compounds are ionized, the partitioning values considered are distribution coefficients (log 
D7.0). In the fact, the partition coefficients of compounds between buffers and model 
membrane phases showed that interactions between charged molecules and biomembranes 
can be complex and include both polar and hydrophobic interactions. In particular, studies on 
partitioning behaviour of ionized compounds between two phases, aqueous buffers and 
phospholipids vesicles (15), they found that certain structural patterns in ionized molecules 
could enhance their partitioning into membrane bilayers. Some of studies were done on a new 
HPLC stationary phase material composed of monolayer of lethicin, the so-called 
immobilized artificial membrane (IAM), confirmed these observations for some basic 
compounds in ionised forms (16). Fortunately, the partitioning or transfer of the drug that can 
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occur in the biological membranes can be studied and simulated in vitro and quantified by 
available physicochemical techniques, using as a model artificial membranes which are 
recently created. Despite the reference method to measure log Poct is shake-flask method, it is 
time consuming, limited in range (-3< log Poct < 4) and outside these limits log Poct values 
become unreliable (17). Hence, during the recent decades, the use of artificial phospholipid 
membranes as a model for biological membranes becomes the subject of intensive research. 
As known that biological membranes are composed of complex mixtures of lipids, sterols, 
and proteins. Therefore, defined artificial membranes may serve as simple models of 
membranes that have many strong similarities with biological membranes. Artificial 
membranes are used to study the influence of drug structure and membrane composition on 
drug partitioning and/or transfer (18). The partition, including affinity, location, and specific 
interaction and diffusion kinetics are the characteristics of membrane permeation with certain 
phospholipids. Because of the complex events involved during drug absorption in vivo, true 
membrane permeability modelling cannot always be created. Therefore, many attempts have 
been made to develop suitable in vitro systems to study the permeation process and its 
dependence on membrane composition and drug physicochemical properties (2). One of these 
attempts is the cell culture model involving Caco-2 cells, which is a human intestinal 
epithelial cell line. The membranes of these cells have useful properties for correlation with in 
vivo data such as enzymatic and transporter systems (19). Therefore, this cell line has been 
proposed and used for the simulation and prediction of intestinal drug absorption after oral 
administration. Kansy and co-workers developed another system called physicochemical 
high-throughput screening system (PC-HTS). This model used a parallel artificial membrane 
permeation assay (PAMPA) for the explanation of passive absorption processes (20). PAMPA 
is based on a 96-well microtiter plate assay that allows the measurements of numerous 
compounds per day. A planar bilayer membrane of egg phosphatidylcholine-decane, for 
example, has been used to study the permeation of monocarboxylic acids (21). Another 
model, drug-liposome partitioning, has been described as a tool for the prediction of 
absorption in the human intestinal tract (22). One of the most important chromatographic 
methods is reversed-phase high performance liquid chromatography (RP-HPLC) where the 
capacity factor (log Kw) derived from isocratic log Kw values by extrapolation to 100 % water. 
This method became a well-accepted method for the determination of the lipophilicity (23-
26). For instance, IAM, fast and reproducible test systems, are used for studying drug-
membrane interaction in relation to drug transport. IAM column chromatography becomes 
even more important in combination combinatorial chemistry and high-throughput screening 
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methods. The columns are packed with single-chain (IAM.PC) or double-chain phospholipids 
(IAM.PC.DD and IAM.PC.DD2), in which the chain was linked by ester or ether groups to 
the glycerol backbone of PC as depicted in figure 1.1. IAM column chromatography has been 
also used to predict the transdermal transport of drugs (27). One more of the attempts of drug 
partitioning determination systems is the immobilized liposome chromatography (ILC). In 
this system, the drug partitioning is determined using liposomes or biomembranes 
immobilized in gel beads by freeze-thawing (28). The lipid used can be phosphatidylcholine, 
phosphatidylserine, egg phospholipid, lipids extracted from human red cell membrane 
vesicles, vesicles from cytoskeleton-depleted human red cell membrane vesicles, and ghosts 

















Figure 1.1. Structures of commercially available immobilized artificial membranes (IAM). 
(Adapted from reference (13)). 
 
In addition to the importance of drug partitioning, understanding of the mechanism and the 
factors influencing the drug release from the drug delivery system and transfer to the site of 
the action is a prerequisite for drug formulation. Nowadays, a very broad range of drug 
molecules are currently in use and new drugs are added to the list yearly. Increasing the 
therapeutic index of the drug and minimizing its side-effects is one of the main goals of any 
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treatment employing xenobiotics. The clinical use of most conventional chemotherapeutics is 
limited because of the inability to deliver therapeutic drug concentrations to the target tissues 
and/or severe and harmful toxic effects on normal organs and tissues. Many approaches have 
been done to dissolve these problems by providing “selective” delivery to the affected tissues. 
The ideal drug delivery system would be to bring the drug only to the site of action. This 
purpose can be achieved by using suitable drug carrier like molecular conjugates and colloidal 
particulates. Colloidal particulates carriers prepared from physical incorporation of the drug 
into a particulate colloidal system such as liposomes, niosomes, micro- and nano-spheres, 
erythrocytes, and polymeric and reverse micelles. Liposomes are one of these carriers which 
have been most studied. Liposomes are biocompatible and biodegradable which make them 
interesting for the researchers. They consist of an aqueous core surrounded by one or more 
bilayers composed of natural or synthetic lipids. Liposomes composed of natural 
phospholipids are biologically inert and weakly immunogenic, and they possess low intrinsic 
toxicity. Further, drugs with different lipophilicities can be encapsulated into liposomes: 
water insoluble drugs are entrapped almost completely in the lipid bilayer, freely water 
soluble drugs are located exclusively in the aqueous compartment, and sparingly water 
soluble drugs (with intermediate log Poct) easily partition between the bilayer and the aqueous 
core (29). Liposomal formulations for water insoluble drugs have been developed and 
successfully introduced into the market (30, 31) since the liposomes being used in intravenous 
rote of administration (32-34). The literatures mentioned that conventional liposomes or 
modified liposomes may change the pharmacokinetic or pharmacodynamic behaviour of the 
drug. These changes may be ascribed to a modified distribution of the liposomal drug in 
tissues (35). Together with a prolongation of the half-life of the drug, active targeting is 
achieved (36, 37). Also the half-life of liposomes in the blood circulation can be reduced by 
passive targeting (i.e. spontaneous or opsonin-mediated uptake) to cell of the Mononuclear 
Phagocyte System (MPS) (38). Moreover, direct targeting of the carrier to the site of action in 
the body could be explored (39, 40). All of these approaches are directed to increase the 
therapeutic index of the liposomal drug. So, the formulation of lipophilic drug in liposomal 
drug delivery system and the transfer kinetics between membranes is of paramount 
importance. But, because of numerous complications arise in the investigation of drug transfer 
in biological systems, due to protein and adsorption of vesicles to membranes, and the 
complex structures of biological membranes and lipoproteins (41, 42), liposomes are the most 
useful simplified models of biological membrane. As a result, an in vitro model was 
established (35, 43) to obtain a better insight into the dynamics of a drug transfer between 
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membranes. This in vitro model consists of drug incorporation into negatively or positively 
charged liposomes (donor) and neutral acceptor liposomes which allow the measurement of 
drug concentration in the acceptor liposomes. Separation of donor and acceptor liposomes of 
samples taken during the experiments was done by using a suitable mini ion-exchange 
column. The principle of this method is shown in figure 1.2. In this model, transfer is 
typically determined by using of a radiolabeled analogue (44, 45). The present study focused 
on one of few approved porphyrins in cancer therapy to date. Porphyrins with a fully 
conjugated macrocycle represent the fundamental group of photosensitizers (PS). The main 
usage of photosensitization is the treatment of different tumor classes which have been found 
to accumulate certain photosensitizers, especially porphyrins, with some selectivity (46, 47). 
The recent development of diode lasers and optical fibres has facilitated the use of light-
sensitive drugs in various therapeutic and experimental applications (48). Corresponding 
techniques are based on irradiation of PS with light, which generates active molecular species 
such as free radicals and singlet oxygen. These short-lived species are highly toxic in a 
biological environment (49) and exhibit restricted diffusion (50). Damage to biomolecules is 
thus determined by the localization of the photosensitizer at the moment of irradiation. The 
ionization state and hydrophobicity of the photosensitizer are the main determinants of 
subcellular localization and, consequently, of photobiological efficacy (51, 52). Membrane 
structures, especially those of mitochondria (53), have been found to be particularly sensitive 
to photosensitization. Most of the currently available PS are amphiphilic or hydrophobic 
compounds that have a tendency to self-aggregate when injected into a physiological aqueous 
environment. Therefore, different delivery systems such as liposomes, Cremophor EL, 
cyclodextrin, or lipoproteins have been employed in order to facilitate the transport of poorly 
water-soluble PS (54-57). The use of specific delivery systems can modulate the 
pharmacokinetics and cellular uptake of PS. For instance, the administration of porphyrins 
incorporated into DPPC liposomes enhances the accumulation and prolongs the retention of 
PS by cultured cells and experimental tumours (58-60). Transport mediated by LDL was 
suggested to enhance the selective accumulation of some PS in the tumour tissue (55, 61, 62). 
The passive cellular uptake of PS and its partition among sub-cellular structures is most likely 
dominated by the dynamics of its permeation through the membranes. Moan and co-workers 
(63) suggested that the low pH value of the interstitial fluid in tumours favours passive 
cellular incorporation of carboxylic porphyrins. This hypothesis gained support from studies 
on the interactions of porphyrins with membrane models (64) and from in vivo experiments 
(65, 66). Consistent with this, multiple studies argue that the transport of hydrophobic 
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compounds between cellular membranes may proceed in the absence of metabolic energy and 
does not require specific protein or ionic interactions (35, 43, 67, 68). In vitro studies have 
shown also that the translocation of porphyrins within cells is quite fast (69). Thus, a precise 
knowledge of the mechanism and the factors controlling the transfer of PS across membranes 
will contribute to the design of liposomes as a drug carrier and to the efficacy of drug delivery 
system, and will consequently improve PDT. However, the complex structure of PS, the large 
size of its macrocycle, and the asymmetric distribution of side chains around the macrocycle 
render usual predictions based on octanol/water partitioning difficult (70). Moreover, many 
complications arise in the investigation of passive transport in biological systems (protein, 
adsorption of vesicles to membranes, and the complex structures of biological membranes and 
lipoproteins). Therefore, we used mini ion-exchange column in vitro model to study 
temoporfin transfer between liposomal membranes. Temoporfin is one of porphyrins 
belonging to the second generation photosensitizers clinically used under the trade name of 
Foscan® (71). Temoporfin (mTHPC) structure is depicted in figure 1.3. After intravenous 
injection, mTHPC has been shown to be effective in PDT in the treatment of squamous cell 
carcinoma of head and neck, in the treatment of early or recurrent oral carcinomas, in the 
palliative treatment of refractory oral carcinomas (72) and in the treatment of primary non-














Figure 1.2. Measurement of temoporfin between liposomal membranes. Micro-columns made 
of Perspex® were filled with DEAE SepharoseTM CL-6B or CM SepharoseTM Fast Flow 
equilibrated in iso-osmolar sucrose. (Adapted from reference (74)). 















Figure 1.3. Chemical structure of temoporfin. 
 
1.2 OBJECTIVES 
As mentioned above, to elicit its pharmacological and therapeutic effects, a drug has to cross 
various cellular barriers by passive diffusion and/or by carrier-mediated uptake. As a result, 
drug design and discovery can not have pharmacodynamic efficacy as the sole criterion of 
optimization but must also take pharmacokinetic considerations into account, in particular 
absorption and distribution. The importance of drug lipophilicity prediction is that it directly 
influences the degree of membrane permeability of solutes. A new approach for studying 
passive absorption and distribution of the drug is based on artificial membranes. Therefore, 
the aim of this thesis was to investigate the partitioning of structurally diverse compounds 
including ionized, non-ionised, and zwitterionic species in addition to some drugs using 
different artificial membranes. Two of artificial membrane models, immobilized artificial 
membrane (IAM.PC.DD2) and XBridgeTM Shield RP18, were chosen using reversed phase 
high performance liquid chromatography (RP-HPLC). The lipophilicity indices obtained from 
the two membranes were compared to the lipophilicity index of n-octanol/water (log Poct). In 
addition to the partitioning studies, the liposomal formulation of a photosensitizing agent 
(Temoporfin; mTHPC) and the kinetics  of transfer between donor liposomes (drug carrier) 
and acceptor liposomes (artificial membrane) using the radiolabeled analogue [14C]mTHPC 
have been studied. The influence of total lipid content, temperature, charge of donor vesicles, 
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and finally fatty acyl chain structure regarding length and saturation of phospholipids in donor 
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2. Materials and Methods 
2.1 Materials  
Acridine, Aniline, N-Ethylamine, 2-Chloroaniline, 2-Aminobiphenyl, Benzyl cyanide, 
Acetophenone, Nitrobenzene, 1-Chloro-2-Nitrobenzene, Benzyl alcohol, 4-Chloro-Benzyl 
alcohol, 3-Chlorophenol, 3-Nitrophenol, 3-Phenylpropionic acid, 4-Phenylbutyric acid, 5-
Phenylvaleric acid, 8-Phenyloctanoic acid, Benzoic acid, 4-Bromobenzoic acid, 3-
Chlorobenzoic acid, 4-Iodobenzoic acid, 1-Naphthoic acid, 4-Methylbenzyl methylamine, 4-
Methylbenzyl ethylamine, 4-Methylbenzyl propylamine, 4-Methylbenzyl butylamine, 4-
Methylbenzyl pentylamine, 4-Methylbenzyl hexylamine, 4-Methylbenzyl heptylamine, 
Aspirin, Antipyrine, Mefenamic acid, Flurbiprofen, Indomethacin, Ketoprofen, Naproxen, 
Phenylbutazone, Promethazine hydrochloride, Metoprolol, Metipranolol, Oxprenolol, 
Penbutolol, Pindolol, Propranolol hydrochloride, Corticosterone, Estrone, Estradiol, 
Hydrocortizone, Hydrocortizone-21-acetate, Progesterone, Dexamethazone, Testosterone, 
Phenytoin, Sulfabenzamide, Sulfacetamide, Sulfamethazine, Sulfamethoxazole, 
Sulfamethoxypyridazine, Sulfanilamide, Uracil and Citric acid. All former compounds were 
obtained from commercial sources (Sigma-Aldrich, Steinheim, Germany; Carl Roth, 
Karlsruhe, Germany; VWR, Leuven, Belgium) in the highest available purity except the (4-
methylbenzyl) alkylamines were synthesized by known procedures (75). 1,2-Dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) 
were purchased from Sygena LTD (switzerland). 1,2-Dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dibehenyl-sn-glycero-3-phosphocholine (DBHPC), 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-stearoyl-2-oleoyl-sn-glycero-3-
phosphocholine (SOPC) and 1,2-dioleoy-3-trimethylammonium-propane sodium salt 
(DOTAP) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 1- Palmitoyl-2-
oleoyl-3-sn-glycero-3-phosphocholine (POPC) was purchased from Genzyme 
Pharmaceuticals (Liestal, Switzerland). Meta-tetrahydroxyphenylchlorin (14C-temoporfin; 
[14C]mTHPC) was kindly provided as a gift from Biolitec AG (Jena, Germany). Cholesterol 
(Chol), Dicetylphosphate (DCP), Trizma® pre-set crystals and Sodium azide were obtained 
from Sigma Chemical Co. (St. Louis, MO. USA). Diethylaminoethyl (DEAE) SepharoseTM 
CL-6B and Carboxymethyl (CM) SepharoseTM Fast Flow preserved in 20% ethanol were 
purchased from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). Sucrose was purchased 
from Carl Roth GmbH (Karlsruhe, Germany). Radioactive substances 3H-Cholesteryl-oleate 
(1mCi/ml) and 14C-Cholesteryl-oleate (100 Ci/ml) were purchased as a stock solution in 
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toluene solvent from GE Healthcare UK Ltd (Amersham radiochemicals) (Buckinghamshire, 
UK). Sodium chloride was purchased from Merck KgaA (Darmstadt, Germany). 
 
2.2 METHODS 
2.2.1 Immobilized Artificial Membrane Chromatography (IAM.PC.DD2) 
2.2.1.1 Determination of Retention Times (tr) 
To measure the capacity factors, a liquid chromatograph was used. The device consisted of a 
HPLC pump System-Gold-125 solvent module, a System-Gold-507e autosampler, and a 
System-Gold-UV/VIS-168 detector (all from Beckmann Coulter, Inc., Fuerton, CA, USA).  
IAM.PC.DD2 (100 mm_4.6 mm i.d., 10 µm) was purchased from Regis Technology (Morton 
Grove, IL, USA).  
 
2.2.1.2 Mobile Phase and Flow Rate 
Two types of mobile phases were used; 1) 0.02M phosphate buffer pH 7.0. 2) 0.02M 
phosphate buffer pH 7.0 mixed with methanol in proportions varying from 70 to 10% (v/v). 
Before mixing the phosphate buffer with methanol, phosphate buffer was   filtered under 
vacuum through a HA-Millipore filter (0.45µm; Millipore, Milford, MA, USA). At room 
temperature and by using the UV/VIS detector at the specific λmax of the each analyte, the 
retention times were identified. The flow rate of 1.0 ml/min was applied for all compounds. 
 
2.2.1.3 Solutions to Be Injected  
Solutes of analytes dissolved in mobile phase in concentrations 10-4 M to 10-3 M to prepare 
the solutions to be injected. The injection volume was 10 µL. Citric acid solution was used as 
the unretained compound to determine t0 in equation (2-1).  
For compounds 22-24 and 26-31 in table 3.1, the log kwIAM values were determined directly in 
the aqueous mobile phase. While for other compounds (lipophilic compounds) a pure aqueous 
mobile phase was tried but the retention times were too long. Thus, to extrapolate log k values 
to 100 % water by application of equation (2-2), four or five different methanol 
concentrations in aqueous solution as mobile phase were used. 
 
log k = log (tr – t0) / t0        [2-1] 
where tr and t0 are the retention times of the solute and of an unretained compound, 
respectively.  
log k = –Sφ + log kwIAM        [ 2-2] 
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where φ is the volume fraction of methanol in the mobile phase, S the slope, and log kwIAM the 
intercept of the regression curve. For hydrophilic compounds, log kwIAM can be determined 
directly by using the aqueous mobile phase. 
 
2.2.2 XBridgeTM Shield RP18 Stationary Phase  
2.2.2.1 Determination of Retention Times (tr) 
The retention times were measured with a liquid chromatograph equipped with a HPLC pump 
SYSTEM GOLD 125 solvent module, a SYSTEM GOLD 507e autosampler and a SYSTEM 
GOLD UV/Vis 168 detector (all from Beckmann Coulter, INC. Fuerton, CA, U.S.A.). The 
column used was an XBridgeTM Shield RP18 (5 cm X 4.6 mm ID, 5µm) from Waters (Milford, 
MA, U.S.A.).  
 
2.2.2.2 Mobile Phase 
The mobile phase comprised 0.02 M phosphate buffer containing methanol in varying 
proportions from 70 to 10% (v/v). For all non-ionizable compounds, the phosphate buffer was 
adjusted at pH 7.0. While for ionisable compounds, the buffer was adjusted at a pH value 
were the neutral form was in large excess for the acidic, ampholytic and basic compounds 
according to their pKa values. A very small amount (0.25% (v/v)) amount of n-octanol was 
added to methanol and n-octanol saturated water was used to prepare the buffer to increase the 
simulation with n-octanol/buffer partitioning (17, 76, 77). Before addition of methanol 
containing n-octanol to phosphate buffer, phosphate buffer was filtered under vacuum through 
a 0.45µm HA Millipore filter (Millipore, Milford, MA, U.S.A.). At room temperature and by 
using the UV/VIS detector at the specific λmax of the each analyte, the retention times were 
calculated.  
 
2.2.2.3 Solutions to Be Injected and Flow Rate 
The injected samples were prepared by dissolving each solute in an appropriate mobile phase 
to get the concentration (10-4 to 10-3 M). The injection volume was 10 µl. Uracil was used as 
an unretained compound. The measurements were done at a flow rate 1.0 for the compounds 
with log Poct values higher than 1 and 0.5 ml/min for the compounds with log Poct lower than 
1.Three different methanol percents were used to extrapolate to log.Kw According to the log 
Poct value of the analyte, methanol percentage was chosen as shown in table 2.1. The capacity 
factor log K was calculated by equation (2-1). From the mean of three measurements of K, log 
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K values were obtained. Extrapolation of log K to 100 % water condition were done applying 
equation (2-3).  
 
log K = –Sφ + log Kw    [2-3] 
where φ is the volume fraction of methanol in the mobile phase, S the slope, and log Kw the 
intercept of the regression curve. For hydrophilic compounds, log Kw can be determined 
directly by using the aqueous mobile phase. 
 
Table 2.1. Concentrations of Organic Modifier (Methanol) used with XBridgeTM Shield RP18 
Stationary Phase  





2.2.2.4 Linear Solvation Free-Energy Relationships Interpretation  
Linear Solvation Free-Energy Relationships (LSERs) concept was developed in (78-82). For   
many chemical systems, there are linear relationships between some properties and the free 
energy of the reaction, the free energy of transition, or the activation energy, parameters 
related to the fundamental parameters of the solvents and solutions. According to this 
concept, chromatographic retention is described by a linear relationship between the log 
retention time (log K) and the parameters that describe the free energy of the reaction. The 
LSERs can be expressed by equation (2-4): 
 
Sp = v·Vw+ p π*+ a α+ b β + c       [2-4] 
 
where Sp is a given molecular property of a neutral organic solute (i.e., log Kw or log Poct in the 
present work). The four structural parameters are the van der Waals volume Vw accounting for 
hydrophobic and dispersive forces, and polar terms known as solvatochromic parameters 
(dipolarity/polarizability π*, H-bond donor acidity α, and H-bond acceptor basicity β) that 
account for polar interactions between solute and solvents. The regression coefficients v, p, a, 
and b reflect the relative contribution of each solute parameter to Sp. 
So, the compounds carefully selected to have relatively rigid structures and well-defined 
structural parameters (Vw, π*, α,and β), and covering broad range of structural parameters and 
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log Poct values (-0.69—5.12) as far as possible so as to establish log Kw/ log Poct relation and 
LSERs equations. 
 
2.2.3 Temoporfin Transfer between Liposomal Membranes 
2.2.3.1 Preparation and Characterisation of Donor and Acceptor Liposomes 
 Liposome preparation was carried out by a well-established thin-film hydration method. 
Chloroform solution of lipids and [14C]mTHPC were dried at a temperature at least ten 
degrees above the gel-to-liquid crystalline phase transition (Tm) of the lipid used by using 
rotavapor Büchi R 114, (Essen, Germany) with a constant rotating speed 60 rpm and under a 
vacuum of 200 mbar for 15 minutes, 100 mbar for 15 minutes, and 50 mbar for 60  minutes 
using vacuum pump Büchi Vacobox B-177 (Essen, Germany) and finally under stream of 
nitrogen gas (until no chloroform smelled). The temperatures were controlled a water bath 
Büchi B-481, (Essen, Germany). The dried film was hydrated by trizma buffer saline (pH7.4 
and 10 mM). The resulting film was completely dispersed by vortexing for 10 minutes (until 
complete dispersion of the dried film). The suspension was equilibrated for two hours; this 
causes the newly formed multilamellar vesicles (MLVs) to be completely hydrated. The 
resulting liposome suspension was extruded through a polycarbonate membrane filter with 
pore diameter 100 nm (83). The final donor vesicle composition was 70 mol % phospholipid, 
10 mol % DCP, 20 mol % of Chol loaded with appropriate amount of [14C-mTHPC]. 
Acceptor vesicles comprised 80 mol % POPC and 20 mol % of Chol. Particle size analysis 
and Zeta potential measurements of the vesicles were determined by photon correlation 
spectroscopy (PCS) using a Zetasizer Nano ZS (Malvern, UK). The samples were diluted 
with Milli-Q water and measured at 25 C. Liposomes were routinely checked for lamellarity 
by Cryo-Transmission Electron Microscopy (Cryo-TEM).  
 
2.2.3.2 Preparation of Ion Exchange Gels (DEAE- SepharoseTM CL-6B and CM 
SepharoseTM Fast Flow)  
DEAE SepharoseTM CL-6B and CM SepharoseTM Fast Flow were bought as 20 % ethanolic 
buffer solution. Appropriate amount of the gel were poured gently in an Erlenmeyer flask 
avoiding air bubbles formation. The material was left to settle down; afterwards the 
supernatant was carefully removed by using a Pasteur pipette connected via tubings to a water 
jet vacuum. The material is washed by three-fold, with trizma buffer saline 10 mM three 
times, and twice with iso-osmolar sucrose buffer (with NaN3 0.02 % as preservative). Finally, 
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the gel was kept in iso-osmolar sucrose buffer (with NaN3 0.02 %) 1:1. at 4°C (all buffers 
were adjusted at pH 7.4). 
 
2.2.3.3 Production of Micro-columns  
Micro-columns, rubber rings, and sealing are washed with Milli-Q-water. A small volume of 
glass wool was used as a plug for the column material. Using a Pasteur pipette, approx. 1.0 ml 
ion exchange suspension was filled in the column. The column is packed with 2 ml of sucrose 
buffer (40 drops/min). The gel was lipid-saturated by eluting an appropriate amount of 
acceptor liposomes. Afterwards the column was eluted with 1.5 ml buffer sucrose buffer (with 
NaN3 0.02 %). 
 
2.2.3.4 Incubation of Donor and Acceptor Liposomes 
In a brown glass vial, donor and acceptor liposome suspensions were mixed. Incubation was 
carried out in Trizma buffer saline, pH 7.4, at specified temperatures with continuous gentle 
stirring. 
 
2.2.3.5 Separation of Vesicles and Drug Transfer Measurements 
Two populations of vesicles, negatively charged “donor” vesicles and neutral “acceptor” 
vesicles were separated by charge on ion-exchange columns by a method based on the 
procedure of Hellings et al. (84) as modified by van den Besselaar et al. (85). After packing 
and saturation of micro-columns, the sample applied to surface of the column (allowed to 
enter the column completely), and eluted with 1.0 ml of the iso-osmolar sucrose buffer. This 
eluate was collected directly into liquid scintillation vials. Samples were added to Rotiszint® 
eco plus liquid scintillation cocktail from Roth (Karlsruhe, Germany) and vortexed well for 1 
minute. After 24 hours, the samples were analyzed by liquid scintillation counting (LSC) of 
[14C]mTHPC using Liquid Scintillation Analyzer Tri-Carb 2800TR (PerkinElmer, USA) . 
 
2.2.3.6 Method Validity 
In a separate experiment, the recovery of the acceptor vesicles and the retention of the donor 
vesicles were investigated. Appropriate amount of radiolabeled donor vesicles containing 3H-
Cholesteryl-oleate and acceptor vesicles containing 14C-Cholesteryl-oleate which were used 
as non-exchangeable markers (35) and mixture of them applied each to six micro-columns. 
The eluates were examined by LSC of non-exchangeable markers. 
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2.2.3.7 Effect of Total Lipid Content on [14C]mTHPC Transfer Kinetics 
For the investigation of [14C]mTHPC transfer mechanism regarding the total lipid 
concentration, the rate of [14C]mTHPC transfer was examined over a wide range of total lipid 
concentrations at 37 oC (±1). The donor vesicles (DMPC:Chol:DCP; 7:2:1) concentration was 
varied over a range 0.1mg, 1mg, and 2mg/ml  while acceptor vesicles (POPC:Chol; 8:2) 
concentration  was varied over a range 1mg, 10mg, and 20mg/ml with a constant ratio 
between donor and acceptor lipid 1:10 mg/mg.  
 
2.2.3.8 Effect of Temperature on [14C]mTHPC Transfer Kinetics 
The temperature dependence of [14C]mTHPC transfer kinetics between large unilamellar 
vesicles at six different temperatures 15, 19, 22, 25,  30, and 37 oC (±1) was investigated. The 
activation energy for this process between 15 and 37 oC was calculated according to the 
Arrhenius equation. Enthalpy, entropy, and free energy were calculated from Van’t Hoff 
equation. Vesicles were mixed at a concentration of 0.1mg of donor vesicle lipid/ml 
(DMPC:Chol:DCP; 7:2:1) and 5.0 mg of acceptor vesicle lipid/mL (POPC:Chol; 8:2). 
 
2.2.3.9 Effect of Donor Liposome Charge on [14C]mTHPC Transfer Kinetics 
The influence of donor liposome charge on [14C]mTHPC transfer kinetics was investigated by 
using positively and negatively charged vesicles as donors at 37±1 oC. Positively charged 
vesicles comprised (DOPC/DOTAP/Chol; 5:3:2) while negatively charged vesicles were 
composed of (DOPC/DCP/Chol; 7:1:2). Acceptor vesicle composition was (POPC:Chol; 8:2). 
Vesicles were mixed at a concentration of 1mg of donor vesicle lipid/ml and 10mg of 
acceptor vesicle lipid/ml. 
 
2.2.3.10 Effect of Donor Lipid Saturation on [14C]mTHPC Transfer Kinetics 
To further evaluate the inner bilayer structure influencing the transfer kinetics of 
[14C]mTHPC, the sensitivity of transfer to variation in acyl chain saturation was examined. 
While keeping the phosphocholine head group and chain length constant, the fatty acids for 
1,2-diacyl species were varied in terms of degree of saturation. The donor vesicles 
composition was 70 mol % of (DOPC or SOPC or DSPC), 20 mol % Chol, 10 mol % DCP. 
Acceptor vesicles comprised 80 mol % POPC and 20 mol % Chol. The donor lipid 
concentration was 1mg/mL while the acceptor lipid concentration was 10mg/ml and the 
temperature was kept at 37 ±1 oC. 
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2.2.3.11 Effect of Acyl Chain Length of Donor Vesicles on [14C]mTHPC Transfer 
Kinetics 
This experiment was an extension to the above one in order to investigate the influence of 
acyl chain length (rigidity) of donor liposomes on transfer [14C]mTHPC between liposomal 
membranes. The phosphocholine head groups of saturated fatty acids were kept the same 
while the 1,2-diacyl species were varied in terms of acyl chain length. The donor vesicles 
composition was 70 mol % of [DMPC (14:0/14:0) or DPPC (16:0/16:0) or DSPC (18:0/18:0) 
or DBHPC (22:0/22:0)], 20 mol % Chol, 10 mol % DCP. Acceptor vesicles comprised 80 mol 
% POPC and 20 mol % Chol. The donor lipid concentration was 1mg/ml while the acceptor 
lipid concentration was 10mg/ml at a temperature of 37 ±1 oC. 
 
2.2.3.12 Calculations 
The transfer curves of the percentage [14C]mTHPC transferred were exponentially fitted using 
Microcal Origin 6.0 software (OriginLab Corporation, US-Northampton) and the exponential 
function:  
 
( )( )01 ttkeyy −−∞ −= .          [2-6] 
Here, y is the percentage of [14C]mTHPC transferred to the acceptor vesicles at time t, and y∞ 
denotes the final percentage of [14C]mTHPC transferred, corresponding to the height of the 
plateau. Conducting the experiments involves a small time offset t0 that is incorporated in 
equation (2-6). The constant K is the apparent rate constant of the transfer. 
In the Appendix, equation (5-1) driven from a simple kinetic transfer model that accounts for 
two different transfer mechanisms, collisions between liposomes (characterized by a rate 
constant Kc) and diffusion of [14C]mTHPC through water (characterized by a rate constant 
Kd). The apparent rate constant is then K = Kd + c Kc where c is the total concentration of 
liposomes (both donor and acceptor) in the aqueous solution. The dependence of the 
measured rate constants K on the concentration of donor and acceptor liposomes suggests the 
transfer mechanism to be either diffusion or collision controlled. 
 
Half lifes were calculated from K as 
 Kt /2ln2/1 =           [2-7]  
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The apparent transfer coefficient (KD→A) of [14C]mTHPC between donor vesicles and acceptor 





CK =→           [2-8] 
where, CA is the amount of [14C]mTHPC in the acceptor vesicles at equilibrium and CD is the 
amount of [14C]mTHPC in the donor vesicles at equilibrium at certain temperature. 
 
The temperature dependence of the equilibrium transfer coefficient is given from Van’t Hoff 









=→         [2-9] 
were, –ΔH/R refers to the slope of the line and ΔS/R is the intercept. ΔH (KJ mol-1) is the 
enthalpy of the transfer, ΔS (J mol-1 K-1) is the entropy of the transfer, T is the absolute 
temperature, and R is the gas constant (8.31 J mol-1 K-1). 
Once ΔH and ΔS are known from the former correlation, the free energy ΔG of the transfer 
can be calculated from the expression: 
 
ΔG = ΔH – TΔS         [2-10] 
 
N.B. All regression analyses were performed via the Microcal Origin statistical software 
package version 6.0 (Microcal Origin software Inc, Northapton, MA, USA).  
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3. RESULTS AND DISCUSSION 
Drugs, whether in formulations which contain more than one phase or in the body, move from 
one liquid phase to another in ways that depend on their relative concentrations (or chemical 
potentials) and their affinities for each phase. So, a drug will move from the blood into 
extravascular tissues if it has the appropriate affinity for the cell membrane and the non-blood 
phase. The movement of molecules from one phase to another is called partitioning. In this 
work, two different artificial membranes, immobilized artificial membrane (IAM.PC.DD2) 
and XBridgeTM shield RP18 stationary phase have been used to study the partitioning of some 
of chemical compounds between the aqueous phase and the non-blood phase. In addition, the 
drug transfer between liposomal drug delivery system and liposomal artificial membrane has 
been studied.  
 
3.1 Immobilized Artificial Membrane (IAM.PC.DD2) 
A set of monofunctional compounds and complex drugs (steroids, non-steroidal anti-
inflammatory drugs, and β-blockers) have been tested to understand the retention mechanism 
of solutes on an IAM stationary phase. This set includes neutral solutes and solutes with 
acidic or basic functionalities which are positively charged or negatively charged at pH 7.0, as 
shown in table 3.1. The influence of different functionalities, lipophilicity, and the charged 
state of the solutes was investigated with respect to retention behaviour of different sets of 
analytes.  
In this part of work, the obtained values of the capacity factors (log kwIAM) were compared 
with the n-octanol/water partitioning values (log Poct). For the ionized compounds, the 
electrostatic interaction with phospholipids was found. 
To simulate the physiologic pH regarding the stationary phase stability (highest pH limit is 
7.5), retention times were measured at pH 7.0 on the IAM.PC.DD2 stationary phase. The 
monofunctional carboxylic acids (22 – 30) and the NSAIDs (31 – 36) are fully negatively 
charged at pH 7.0 according to the pKa values of the compounds shown in table 3.1, whereas 
basic compounds including (4-methylbenzyl) alkylamines (37 – 43) and β-blockers (44 – 49) 
are fully positively charged. For the very weak bases and acids (1 – 5, 12, and 13), a neutral 
form at this pH was found. The pKa values, charge state of the compounds, the partition 
coefficient (log Poct), and distribution coefficient at pH 7.0, namely log D7.0 calculated from 
pKa and log Poct values, are shown in table 3.1.  
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3.1.1 Relationship between log k and φ 
A pure aqueous mobile phase was used to elute the analytes 22 – 24 and 26 – 31, whereas for 
the other compounds, four or five different methanol concentrations were added to the 
aqueous mobile phase for the extrapolation to log kwIAM values. Considering the range of the 
eluent composition studied, good linear relationships between log k and φ were attained. The 
squared correlation coefficient was higher than 0.99, except for the log kwIAM of compounds 
numbers 3, 4, 10, and 46 in table 3.1 (R2=0.98). The log kwIAM values are presented in table 
3.1 together with other physicochemical parameters.  
 
Table 3.1. The physicochemical parameters of the investigated solutes  
 Compounds Log Pocta) pKa a) log D7.0b) charge 
state 
log kwIAM c) 
1 Acridine 3.40 5.58 3.40 N 2.42 
2 C6H5NH2 0.90 4.60 0.90 N 0.26 
3 C6H5NHC2H5 2.16 5.12 2.16 N 1.04 
4 2-Cl-C6H4NH2 1.91 2.64 1.91 N 1.14 
5 2-NH2-C6H4-C6H5 2.84 3.82 2.84 N 2.02 
6 C6H5CH2CN 1.56 N 1.56 N 0.94 
7 C6H5-CO-CH3 1.58 N 1.58 N 0.86 
8 C6H5NO2 1.85 N 1.85 N 0.99 
9 2-ClC6H4NO2 2.24 N 2.24 N 1.58 
10 C6H5CH2OH 1.08 N 1.08 N 0.58 
11 4-Cl-C6H4CH2OH 1.96 N 1.96 N 1.21 
12 3-Cl-C6H4OH 2.49 9.11 2.48 N 1.77 
13 3-NO2-C6H4-OH 2.00 8.40 1.96 N 1.38 
14 Corticosterone 1.94 N 1.94 N 1.67 
15 Dexamethasone 1.83 N 1.83 N 1.79 
16 Estradiol 4.01 N 4.01 N 2.65 
17 Estrone 3.13 N 3.13 N 1.92 
18 Hydrocortisone 1.55 N 1.55 N 1,35 
19 Hydrocortisone-21-acetate 2.19 N 2.19 N 1.78 
20 Progestrone 3.87 N 3.87 N 3.01 
21 Testosterone 3.29 N 3.29 N 2.51 
22 C6H5(CH2)2COOH 1.89 4.52 -0.59 - -0.25 
23 C6H5(CH2)3COOH 2.42 4.72 0.14 - 0.06 
24 C6H5(CH2)4COOH 2.85 4.55 0.40 - 0.43 
25 C6H5(CH2)7COOH 4.09 5.03 2.12 - 2.02 
26 C6H5COOH 1.96 4.20 -0.84 - -0.62 
27 4-BrC6H4COOH 2.86 3.97 -0.17 - 0.32 
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28 3-ClC6H4COOH 2.71 3.83 -0.46 - 0.06 
29 4-IC6H4COOH 3.13 3.96 0,09 - 0.51 
30 1-Naphthoic acid 3.10 3.69 -0.21 - 0.13 
31 Aspirin 1.13 3.48 -2.39 - -0.15 
32 Flurbiprofen 3.81 3.91 0.72 - 1.78 
33 Ketoprofen 2.77 4.29 0.06 - 1.26 
34 Naproxen 3.06 4.15 0.21 - 1.35 
35 Indomethacin 4.27 4.50 1.77 - 2.37 
36 Mefenamic acid 5.12 4.33 2.45 - 2.35 
37 4-CH3C6H4CH2NHCH3 1.96 9.93 -0.97 + 0.96 
38 4-CH3C6H4CH2NHC2H5 2.38 10.04 -0.66 + 1.02 
39 4-CH3C6H4CH2NHC3H7 2.96 9.98 -0.02 + 1.30 
40 4-CH3C6H4CH2NHC4H9 3.49 9.98 0.51 + 1.87 
41 4-CH3C6H4CH2NHC5H9 4.26 10.08 1.18 + 2.27 
42 4-CH3C6H4CH2NHC6H11 4.96 10.17 1.79 + 2.77 
43 4-CH3C6H4CH2NHC7H13 5.12 10.02 2.10 + 2.92 
44 Metoprolol 1.95 9.63 -0.68 + 1.45 
45 Metipranolol 2.81 9.54 0.27 + 1.78 
46 Oxprenolol 2.51 9.57 -0.06 + 1.70 
47 Penbutolol 4.62 9.92 1.70 + 3.70 
48 Pindolol 1.75 9.54 -0.79 + 1.31 
49 Propranolol 3.48 9.53 0.95 + 2.48 
a) Taken from references (86-89). b) Calculated according to log D7.0 = log Poct– log (1 + 10pKa – pH) for bases and 
log D7.0 = log Poct– log (1 + 10pH – pka) for acids. c) n = 3, s.d. ≤ 0.05. N = Neutral 
 
3.1.2 Relationship between log kwIAM and log Poct 
No correlation was found for all compounds under investigation in one equation. However, 
good correlations for neutral compounds or structurally related compounds were found. The 
resulting equations for the relation between log kwIAM and log Poct are shown as follows below 
in equations 3-1 – 3-5. In these equations, 95% confidence limits are in parentheses, n is the 
number of compounds, R2 the squared correlation coefficient, s the standard deviation, and F 
Fisher’s test. Figure 3.1 shows correlation between log kwIAM and log Poct. 
 
3.1.2.1 Relationship between log kwIAM and log Poct for the neutral compounds 
For the neutral molecules (1-21 in table 3.1), reasonable correlation was obtained when all 
neutral molecules are treated as a one set (R2 = 0.87). While by removing the steroids (14-21) 
from this list, quite good relationship was established for the 13 mono-functional molecules 
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(1-13) (R2=0.95). This result indicates that the correlation significance for neutral solutes is 
increased by decreasing the structural diversity of the compounds. 
 
log kwIAM = 0.77 (±0.13) log Poct – 0.19 (±0.33)      [3-1] 
n=21, R2=0.87, s=0.26, F=130 
 
3.1.2.2 Relationship between log kwIAM and log Poct for the β-blockers  
In terms of the β-blockers analytes (44-49 in table 3.1), equation 3-2 and figure 3.1 show that 
the correlation line is identical to that one of the neutral compounds. Barbato and co-workers 
reported the same results when ten β-blockers on three different types of IAM columns (90) 
were investigated. This result indicates that although the β-blockers compounds are 
completely ionized bearing positive charges under the experimental conditions, they can 
interact strongly with phospholipids like neutral compounds with the same log Poct values. 
This means that rather than lipophilicity, the retention behaviour of the β-blockers under study 
on IAM:PC:DD2 stationary phase is controlled by electrostatic interaction between positively 
charged amines of β-blockers and negatively charged phosphates of phospholipids as 
mentioned by Avdeef et al. (91) and Barbato et al. (90, 92).  
 
log kwIAM = 0.84 (±0.16) log Poct – 0.34 (±0.48)      [3-2] 
n=6, R2=0.97, s=0.18, F=115 
 
3.1.2.3 Relationship between log kwIAM and log Poct for the 4-methylbenzyl alkylamines  
Although these substances are positively charged under these experimental conditions like β-
blockers, the interaction of the seven positively charged (4-methylbenzyl) alkylamines (37 – 
43 in table 3.1) with the phospholipids on IAM.PC.DD2 stationary phase was weaker than 
that of the β-blockers and neutral compounds having the same log Poct values. This 
phenomenon means that the strength of the electrostatic interaction between charged amines 
and phospholipids membrane depends on the whole chemical structure of the molecule. These 
results can be seen from equation 3-3 and figure 3.1. 
 
log kwIAM = 0.65 (±0.07) log Poct – 0.46 (±0.27)      [3-3]  
n=7, R2=0.98, s=0.11, F=320 
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3.1.2.4 Relationship between log kwIAM and log Poct for the NSAIDs  
It is clear from figure 3.1 and equation 3-4 that the negatively charged NSAIDs (31-36 in 
table 3.1) under investigation were retained on IAM:PC:DD2 stationary phase less than the 
positively charged compounds. This result is in contrast with the result from the study of 
Barbato et al. on IAM.PC.MG stationary phase (93). Barbato and co-workers found that the 
correlation between log kwIAM and log Poct for NSAIDs (with carboxylic function not directly 
linked to the aromatic ring) and neutral compounds resulted in a good regression line. 
Whereas, in this study (on IAM.PC.DD2 stationary phase) showed two different regression 
lines for NSAIDs and neutral compounds. This indicates that the interaction of NSAIDs under 
investigation is weaker than that of neutral compounds having the same log Poct values on 
IAM.PC.DD2 stationary phase. Moreover, it could be seen that the regression lines of 
negatively charged NSAIDs, especially 32-35 in table 3.1, and the positively charged (4-
methylbenzyl) alkylamines are identical. 
 
log kwIAM = 0.66 (±0.16) log Poct – 0.72 (±0.55)      [3-4] 
n=6, R2=0.95, s=0.24, F=73 
 
3.1.2.5 Relationship between log kwIAM and log Poct for the monofunctional carboxylic 
acids  
With the exception of 8-Phenyloctanoic acid (25 in table 3.1), the retention of monofunctional 
carboxylic acids (22 – 30) which are negatively charged at pH 7.0 were also less than the 
retention of neutral compounds like the negatively charged NSAIDs behaviour on 
IAM.PC.DD2 stationary phase column. Moreover, although the mono-functional carboxylic 
acids (22 – 30) are negatively charged at pH 7.0, they showed less retention time than the 
negatively charged NSAIDs on IAM.PC.DD2 stationary phase column. This difference in 
retention behaviour could bee seen from different regression lines between log kwIAM and log 
Poct in figure 3.1. Also it is clear that the correlation coefficient of equation 3-5 is less 
significant (R2=0.86), indicating that the retention behaviour of group of molecules can not be 
well known by their log Poct values. In terms of the molecule 8-phenyloctanoic acid (25 in 
table 3.1), although it bears a negative charge, it showed a retention behaviour more than all 
of mono-functional carboxylic acids mimicking the retention behaviour of NSAIDs. This may 
be ascribed to the fact, that as the chain length of nonpolar aliphatic compounds increases, the 
partition coefficient (P) increases by factor of 2-4 per each methylene group (94). 
Consistently with this fact, 8-Phenyloctanoic acid is more lipophilic than the other mono-
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functional carboxylic acids because it has (-CH2-)7 groups. Owing to the hydrocarbon chain, it 
displays a high affinity to the phospholipids in IAM.PC.DD2 stationary phase more than the 
affinity to the aqueous mobile phase. 
 
 log kwIAM = 1.02 (±0.31) log Poct– 2.54 (±0.89)      [3-5]  
n=9, R2=0.86, s= 0.29, F=43 
Figure 3.1. The correlation between log kwIAM values from IAM.PC.DD2 stationary phase at 
pH 7 and log Poct values for the compounds investigated. 
 
3.1.3 Relationship between log kwIAM and log D7.0 on IAM.PC.DD2 Column  
In terms of NSAIDs and (4-methylbenzyl) alkylamines dealt in this study, the n-octanol/water 
partition coefficient (a ratio of concentrations of un-ionized compound between the two 
solutions) and n-octanol/water distribution coefficient (the ratio of the sum of the 
concentrations of ionized plus un-ionized forms of the compound in the two solutions) values 
are highly interrelated. As a result, the correlation between the retention behaviour on 
IAM.PC.DD2 stationary phase (log kwIAM) and the n-octanol/water distribution coefficient 
(log D7.0) was not dealt here any longer. While for β-blockers, the significance of the 
correlation between log kwIAM and log D7.0 values decreased in comparison to that between log 
kwIAM and log Poct. In contrast, a high significant correlation equation is found out between log 
kwIAM and log D7.0 values for the monofunctional carboxylic acids. This difference in 
significance can be noted from the comparison between the correlation coefficients of 
equation 3-5 and equation 3-6. This notion means that the n-octanol/water distribution 
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coefficient (log D7.0) values can be a good interpretation for the retention behaviour of this set 
of molecules on IAM.PC.DD2 stationary phase.  
 
log kwIAM = 0.82 (±0.16) log D7.0+ 0.25 (±0.13)      [3-6] 













Figure 3. 2. The correlation between log kwIAM values from IAM.PC.DD2 stationary phase at 
pH 7 and log D7.0 values for the compounds investigated. 
 
To elucidate the extra interaction between the charged molecules and the phospholipids of 
IAM.PC.DD2, the correlation between log kwIAM and the distribution coefficient log D7.0 of 
the compounds under study was established in figure 3.2. The non-ionised compounds 
showed the least retention on IAM.PC.DD2 stationary phase as can be seen from figure 3.2. 
In another words, the ionized molecules showed stronger retention behaviour than the neutral 
compounds with the same log D7.0 values, to a different degree, depending on their charge 
type and structural characteristics. With respect to the charged solutes, the positively charged 
molecules are more strongly retained than the negatively charged one. As explained by 
Avdeef et al. for the liposomal membrane/water partitioning of ionized drugs (91), the charge 
distribution in the phospholipid membrane is anisotropic; as the ionized species moves in the 
direction of the aqueous exterior of the membrane; the first charges it experiences are those of 
the negatively charged phosphates. Further movement would bring the ionized drug substance 
in the vicinity of the positively charged trimethyl ammonium groups. Electrostatic pairing of 
charges would need a greater movement for weak acids, compared to weak bases. Therefore, 
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the negatively charged solutes have lesser affinity for phosphatidylcholine-based membranes 
than positively charged solutes. The results from this study with the IAM.PC.DD2 stationary 
phase verified this point. In addition, the structural characteristics influence also in the 
retention behaviour of the ionized solutes which bearing the same charge on the 
IAM.PC.DD2 phase. For instance, β-blockers are slightly more retained than (4-
methylbenzyl) alkylamines, which is also stated by Bertschinger et al. in their study (87). 
Also for the negatively charged solutes, monofunctional carboxylic acids are less retained 
than NSAIDs (except mefenamic acid (36) in table 3.1), verifying the influence of the 
structural characteristics of the solutes on the electrostatic interaction.  
 
3.2 XBridgeTM Shield RP18 Stationary Phase 
The two most popular HPLC phase, C18 and C8, are the workhorses of liquid chromatography 
method development. Useful for a wide variety of separations, these columns are familiar to 
all separation scientists. XBridge C18 and C8 offer methods development flexibility. By 
employing trifunctional bonding and advanced endcapping, excellent reproducibility, 
performance, and column lifetime across the entire pH range (1-12) is observed. In recent 
times, a novel RP-HPLC column (XBridgeTM Shield RP18) produced by organic/inorganic 
Hybrid Particle Technology has become available. The patented Shield Technology 
incorporates a carbamate group embedded into the bonded phase that “shields” surface 
silanols. Additionally, it functionally enables compatibility with fully aqueous mobile phases 
without risk of pore dewetting, resulting in reliable and robust retention. Since the column 
shows a wide pH resistance (1—12), it is expected to measure with this column lipophilicity 
also for basic molecules like for neutral and acidic ones. 
 
3.2.1 Selection of the Compounds to Be Examined  
A highly informative interpretation from the retention of solutes on RP-HPLC stationary 
phases can be attained by linear solvation free-energy relationships (LSERs). Also the 
relationships have been applied in estimation of partitioning mechanisms of molecules in 
different organic/aqueous biphasic systems (80-82). The LSERs can be expressed by equation 
3-7. 
 
Sp = v·Vw+ p π*+ a α + b β + c       [3-7] 
where Sp is a given molecular property of a neutral organic solute (i.e., log Kw or log Poct in 
the present work). The four structural parameters are the van der Waals volume Vw accounting 
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for hydrophobic and dispersive forces, and polar terms known as solvatochromic parameters 
(dipolarity/polarizability π*, H-bond donor acidity α, and H-bond acceptor basicity β) that 
account for polar interactions between solute and solvents. The regression coefficients v, p, a, 
and b reflect the relative contribution of each solute parameter to Sp. In the present study, 
relatively rigid structures and well-known structural parameters (Vw, π*, α, and β) molecules 
are carefully chosen to be investigated. These solutes cover a broad range of structural 
parameters and log Poct values (-0.69—5.12) as far as possible so as to establish log Kw /log 
Poct relation and LSERs equations. The parameters were written in table 3.2. Figure 3.3 shows 
that the values of parameters for the selected compounds were distributed in a wide range. 
 
3.2.2 Relationship between log K and φ  
Excluding nitrobenzene and ketoprofen (15 and 32 in table 3.2) (R2=0.96) and 4-
methylbenzyl), ethylamine and 5-phenylvaleric acid (7 and 24 in table 3.2) (R=0.97), the 
squared correlation coefficient (R2) was higher than 0.99 for all compounds. This means, an 
excellent linear relationship between log K and φ was found for majority of the compounds 
tested on the XBridgeTM Shield RP18 stationary phase. The rightmost column in table 3.2 
includes the log Kw values of the molecules for this stationary phase. 
 
3.2.3 Correlation between log Poct and log Kw  
The correlation between log Poct and log Kw values on the XBridgeTM Shield RP18 stationary 
phase for the 40 compounds can be seen from equation 3-8 and figure 3.4. 
 
log Poct=1.03 (±0.07) log Kw + 0.48 (±0.15)       [3-8] 
n=40, q2=0.96, R2=0.96, s=0.26, F=968 
where the values in the parentheses are the 95% confidence limits; n, q2, R2, s and F are the 
number of compounds, the cross-validated correlation coefficient, the squared correlation 
coefficient, and the standard deviation and Fisher’s test, respectively. 
 
It can be noted from the results that for the whole set of neutral, acidic, ampholytic, and basic 
compounds, the log Kw values obtained from the XBridgeTM Shield RP18 phase are 
significantly well correlated with the log Poct values although the log Kw values are not the 
same as the log Poct values as indicated by the intercept (+0.48) of equation 3-8. This means 
that the determination of n-octanol/water partition coefficient by fast and reliable RP-HPLC 
with XBridgeTM Shield RP18 column along a wide pH range (1-12) is possible. 
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The slope of equation 3-8 which almost equal to unity means a significant correlation between 
log Poct and log Kw on the XBridgeTM Shield RP18 phase. This result is good correlation 
between the partitioning process in n-octanol/water and the chromatographic retention process 
on this stationary phase (17). One can speculate, that this similarity is originating from the 
amido groups embedded in the stationary phase. The silica-based Discovery-RP-Amide-C16 
phase produced also a significant correlation between log Poct and log Kw for neutral and 
acidic drugs. This may be also ascribed to that it has the same amido groups as the XBridgeTM 
Shield RP18 phase (17, 77). A highly significant correlation between the log Kw values 
obtained with two stationary phases, silica-based Discovery-RP-Amide-C16 phase and 
XBridgeTM Shield RP18 phase, for the 32 common solutes presented in equation 3-9 and 
figure 3.5. This result confirm that the polar amido groups embedded in the alkyl chains of the 
two stationary phases are main the reason to yield a good correlation between log Kw values 


















Figure 3.3. Distribution of the 40 investigated compounds (table 3.2) in the parameter spaces 
of van der Waals volume Vw, dipolarity/polariability π*, H-bond acceptor basicity β and H-
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Table 3.2. Investigated compounds and their physicochemical parameters 
No. Solutes  Vw a,b) π* a,c) β a,d) α a,e) log Pocta) pKaf) 
log Kw g) on 
XBridgeTM 
Shield RP18 
 Model solutes        
 Bases        
1 Acridine 174.9 1.57 0.52 0.00 3.40 5.58 2.42 
2 C6H5NH2 98.0 0.94 0.41 0.06 0.90 4.60 0.70 
3 C6H5NHC2H5 133.0 0.78 0.45 0.03 2.16 5.12 1.48 
4 2-Cl-C6H4NH2 111.8 1.06 0.41 0.06 1.91 2.64 1.30 
5 2-NH2-C6H4-C6H5 173.9 1.55 0.41 0.18 2.84 3.82 2.26 
6 4-CH3C6H4CH2NHCH3 149.5 0.80 0.70 0.08 1.96 9.93 1.10 
7 4-CH3C6H4CH2NHC2H5 166.1 0.80 0.70 0.08 2.38 10.04 1.35 
8 4-CH3C6H4CH2NHC3H7 183.4 0.80 0.70 0.08 2.96 9.98 1.75 
9 4-CH3C6H4CH2NHC4H9 199.4 0.80 0.70 0.08 3.49 9.98 3.15 
10 4-CH3C6H4CH2NHC5H9 217.7 0.80 0.70 0.08 4.26 10.08 3.75 
11 4-CH3C6H4CH2NHC6H11 234.2 0.80 0.70 0.08 4.96 10.17 4.36 
12 4-CH3C6H4CH2NHC7H13 251.8 0.80 0.70 0.08 5.12 10.02 4.96 
 Neutrals        
13 C6H5CH2CN 121.5 1.22 0.45 0.00 1.56  1.24 
14 C6H5-CO-CH3 122.3 1.12 0.51 0.00 1.58  1.08 
15 C6H5NO2 107.6 1.01 0.28 0.00 1.85  1.36 
16 2-ClC6H4NO2 122.0 1.13 0.28 0.00 2.24  1.93 
17 C6H5(CH2)2C6H5 196.9 0.99 0.20 0.00 4.80  4.00 
18 C6H5CH2OH 111.6 0.84 0.58 033 1.08  0.65 
19 4-Cl-C6H4CH2OH 126.3 0.96 0.58 0.33 1.96  1.39 
 Acids        
20 3-Cl-C6H4OH 107.8 0.84 0.16 0.69 2.49 9.11 2.08 
21 3-NO2-C6H4-OH 112.9 1.54 0.23 0.79 2.00 8.40 1.53 
22 C6H5(CH2)2COOH 146.0 1.12 0.45 0.60 1.89 4.52 1.27 
23 C6H5(CH2)3COOH 162.4 1.12 0.45 0.60 2.42 4.72 1.75 
24 C6H5(CH2)4COOH 179.8 1.12 0.45 0.60 2.85 4.59 2.20 
25 C6H5COOH 111.8 0.74 0.40 0.59 1.96 4.20 1.31 
26 4-BrC6H4COOH 133.8 0.94 0.40 0.59 2.86 3.97 2.31 
27 3-ClC6H4COOH 126.2 0.86 0.30 0.59 2.71 3.83 2.17 
28 4-IC6H4COOH 141.6 0.96 0.42 0.59 3.13 3.96 2.53 
29 1-Naphthoic acid 158.5 1.05 0.40 0.59 3.10 3.69 2.52 
 Drugs        
30 Flurbiprofen 223.1 1.78 0.49 0.60 3.81 3.91 3.62 
31 Indomethacin 283.5 1.86 1.29 0.60 4.27 4.50 3.76 
32 Ketoprofen 239.1 2.12 0.99 0.60 2.77 4.29 2.18 
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33 Naproxen 216.5 1.64 0.79 0.60 3.06 4.15 2.24 
34 Phenytoin 228.3 1.45 1.02 0.60 2.68 8.33 1.57 
35 Sulfabenzamide 233.6 2.48 1.25 0.33 1.46 1.70/
4.57 
1.09 
36 Sulfacetamide 174.8 2.58 1.25 0.33 -0.16 1.78/    
5.28 
-0.51 
37 Sulfamethazine 237.5 2.72 1.90 0.33 0.25 2.73/
7.52 
0.01 
38 Sulfamethoxazole 207.5 2.59 1.64 0.36 0.72 2.28/
5.68 
0.60 
39 Sulfamethoxypyridazine 229.6 2.93 2.38 0.33 0.35 2.09/
7.02 
0.17 
40 Sulfanilamide 139.1 1.89 1.26 0.60 -0.69 2.15/
10.42 
-0.87 
a) Taken from reference (95). b) Van der Waals volume. c) Dipolarity/polarizability. d) H-bond acceptor 
basicity. e) H-bond donor acidity. f) Taken from references (86, 87, 96). g) 0.01 ≤ S.D ≤ -0.15. 
 
Table 3.3. Compounds in the Test Set 
 Solutes log Pocta) pKab)  log Kwc) on XBridgeTM Shield RP18 log P d) 
41 Antipyrine 0.17 -0.04 -0.04 0.44 
42 Aspirin 1.19 0.40 0.40 0.89 
43 Estradiol 4.01 3.36 3.36 3.94 
44 Hydrocortisone 1.55 0.81 0.81 1.31 
45 Mefenamic acid 5.12 4.34 4.34 4.95 
46 Metoprolol 1.95 1.00 1.00 1.51 
47 Penbutolol 4.62 4.06 4.06 4.66 
48 Phenylbutazone 3.16 2.35 2.35 2.90 
49 Pindolol 1.75 9.54 0.71 1.21 
50 Progestrone 3.57 3.37 3.37 3.95 
51 Promethazine 4.81 4.08 4.08 4.68 
52 Propranolol 3.48 2.78 2.78 3.34 
53 Testosterone 3.32 268 2.68 3.24 
a) Taken from (17, 87). b) Taken from (86). c) 0.01 ≤ SD ≤ 0.15 d) Partition coefficient predicted by equation 10. 
 
log Kw (XBridgeTM Shield RP18) = 1.03 (±0.06) log Kw (Discovery RP Amide C16) + 0.17 (±0.12) [3-9] 


















Figure 3.4. Relationship between log Poct and log Kw obtained with the XBridgeTM Shield 
RP18 stationary phase. 
 
To judge, if the capacity factor (log Kw) resulted from the XBridgeTM Shield RP18 can predict  
lipophilicity (log Poct), a group of 13 molecules listed in table 3.3 with a wide structural 
diversity and known log Poct values were investigated to found the predictive power of 
equation 3-8. The rightmost column and the second rightmost column in table 3.3 contain the 
log Kw values from the XBridgeTM Shield RP18 phase and the log Poct values predicted by 
equation 3.8. It can be seen from these new values predicted by equation 3.8 that the 
lipophilicity index log Kw gives an acceptable evaluation of log Poct as shown in equation 3-
10. This is considered a successful application of the XBridgeTM Shield RP18 stationary phase 
in log Poct prediction under the present experimental conditions. 
 
log Poct = 0.94 (±0.09) log P (est. from log Kw) + 0.27 (±0.30)     [3-10] 
n=13, q2=0.98, R2=0.98, s=0.25, F=429 
 
Since the XBridgeTM Shield RP18 phase can give log Kw values highly correlated with log Poct 
values for all types of compounds, acidic, basic, and neutral with a wide range of log Poct, it 
can be concluded that XBridgeTM Shield RP18 stationary phase can be used instead of the 
shake-flask method in determination of lipophilicity. 
 







5  y = 1.03x + 0.48
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3.2.4 Comparison by LSERs Analysis between the Retention Mechanism on the 
XBridgeTM Shield RP18 Phase and the Partitioning Mechanism in n-octanol/water  
For the 40 analytes with known solvatochromic parameters listed in table 3.2, the log Kw 
values obtained with the XBridgeTM Shield RP18 stationary phase were analyzed using linear 
solvation free-energy relationships (LSERs). The structural properties governing retention 
mechanism on XBridgeTM Shield RP18 stationary phase were described by obtained 
statistically significant equations 3-11 and 3-11a. 
 
Log Kw= 2.61·10-2 (±0.41·10-2) Vw – 0.64 (±0.48) π* 
– 2.00 (±0.66) β – 0.09 (±0.65) α– 0.32 (±0.65)     [3-11] 
n=40, q2=0.84, R2=0.85, s=0.51, F=52 
 
After the removal of the non-significant variable α, 
log Kw = 2.61 10-2 (±0.41·10-2) Vw – 0.66 (±0.45) π* 
– 1.98(±0.64) β – 0.33 (± 0.64)       [3-11a] 
n=40, q2=0.84, R2=0.85, s=0.50, F=69 
 
From the equation 3.11a, it can be seen that the solute’s molecular volume (Vw, an expression 
of its hydrophobicity) and H-bond acceptor basicity (β) are the main factors governing the 
retention of solutes on XBridgeTM Shield RP18 stationary phase. On the other hand, the 
influence of dipolarity/polarizability (π*) is small while H-bond donor acidity (α) is trivial. 
 
To compare between the log Kw values obtained with the XBridgeTM Shield RP18 stationary 
phase and the log Poct values of the same set of compounds, the log Poct were also analyzed by 
LSERs as in equations 3-12 and 3-12a. 
 
log Poct = 2.76 10-2 (±0.35 10-2) Vw – 0.83 (±0.40) π* 
-2.06(±0.55) β – 0.05(±0.55) α– 0.26(±0.55)      [3-12] 
n=40, q2=0.90, R2=0.91, s=0.43, F=86 
 
After removal of the non-significant variable α, 
log Poct = 2.76 10-2 (±0.34 10-2) Vw – 0.84 (±0.37) π* 
– 2.05 (±0.53) β – 0.25 (±0.54)       [3-12a] 
n=40, q2=0.90, R2=0.91, s=0.42, F=118 















Figure 3.5. Relationship between log Kw values obtained with the XBridgeTM Shield RP18 and 
Discovery RP Amide 16 stationary phases (the data for discovery RP Amide 16 were cited 
from reference (97). 
 
It is also clear from equation 3.12a that also α has no significance and π* is less significance, 
while Vw and β are the two main structural properties that govern the partitioning mechanism 
in n-octanol/water. This means that the same balance of intermolecular forces is encoded by 
log Poct and log Kw measured on the XBridgeTM Shield RP18 phase. This finding indicates the 
high significant correlation between these two parameters as shown in equation 3-8. 
 
3.3 Temoporfin (mTHPC) Transfer between Liposomal Membranes 
3.3.1 Method Validity  
The donor and acceptor liposomes prepared by extrusion through a 100 nm polycarbonate 
membrane had polydispersity indices less than 0.10 indicating a high homogeneity of the 
vesicle sizes. During the time of use of the formulations for the transfer experiments, there 
were virtually no changes in the particle sizes and polydispersity values. More than 93 % of 
the donor liposomes were unilamellar, the remaining small fraction showing only 
bilamellarity.as shown from figure 3.6. In order to evaluate the validity of the method in terms  
of donor retention and acceptor recovery, a control experiment was carried out using non-
exchangeable markers. With pre-equilibrated columns, 99% of donor liposomes (charged 
vesicles) were retained as shown in figure 3.7a. For the acceptor liposomes (neutral vesicles), 
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91-99% were recovered in the eluate (see figure 3.7b). Acceptor recovery is a significant 
improvement over the recoveries (40-70%) reported by van den Besselaar et al. (85) and 




Figure 3.6. Cryo-Transmission Electron Microscopy of large unilamellar liposomes (these 
pictures done by Frank Steiniger, FSU Jena) 
 
3.3.2 Effect of Total Lipid Content on [14C]mTHPC Transfer Kinetics 
Because the release of drug from a drug delivery system is an important step in the inter-
membrane transfer of lipophilic drugs, the assessment of the release kinetics can be predictive 
for the adsorption parameters of the drugs (35). It is well known, that with increasing 
incubation time, photosensitizers (temoporfin) can migrate from the plasma membrane to the 
more sensitive stores within the cell (70). Temoporfin was observed to accumulate in 
mitochondria of myeloid leukemia cells (98). In this work, liposomes were used as a model of 
biological membranes. For better mimicking the lipid composition of biological membranes; 
cholesterol has been added in all cases. It must be pointed out, that 20 mol % of cholesterol 
has been chosen in order to avoid drastic changes of the liposome main properties: at 
cholesterol concentration lower than 33 mol % of the total lipid moles, no effect is observed 
on the size of liposomes and the phase transition is not inhibited (99). 
To identify the mTHPC transfer mechanism, the rate of transfer was examined over a range of 
total lipid concentrations. Table 3.4 and figure 3.8 report the results of mTHPC transfer 
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experiments in which the donor: acceptor vesicle ratio was kept constant, while the total lipid 




























Figure 3.7. (a) Donor retention % and (b) Acceptor recovery %  in ion-exchange micro-
column model based drug transfer experiments using negatively charged liposomes  as donor 
(DMPC/DCP/Chol, 7:1:2) and neutral liposomes as acceptor (POPC/Chol, 8:2). 
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The transfer (figure 3.8a) can be described very well by a simple exponential function. To 
compare with the transfer model presented in the appendix, in figure 3.8b the rate constant K 
as a function of the total lipid concentration have been plotted (as stated in table 3.4). Also a 
linear fit is shown in figure 3.8b, which relates the experimental data to the theoretically 
predicted relation for K. The fit exhibits both a finite slope and finite intercept, suggesting 
that transfer through both diffusion and collision mechanisms could contribute to the 
experimentally observed data. However, the reliability of this interpretation is weakened by 
small number of data points and by the basic model (see appendix). In particular, the possible 
non-ideality of the mixture of drug molecules in donor and acceptor vesicles (including self-
assembly and aggregation phenomena) is not accounted for by the theoretical model in the 
appendix or by any other previous modelling attempt. There is clearly a need to develop and 
make available more elaborate modelling approaches. The model in the appendix does not 
account for the small offset at t = 0 as well (for example visible in figure 3.8 and figure 3.10). 
This may be due to drug bound to the surface, which can be transferred fast to the acceptor 
liposomes.  
The inter-membrane transfer phenomenon was firstly described as part of membrane 
biochemistry studies with liposomes as model membranes for biological membranes (35). The 
assessment of inter-membrane transfer properties yields valuable information about the use of 
liposomes as solubilisers or as targeting devices for lipophilic drugs. In addition, the 
transferring properties may be predictive to some extent for the distribution and retention 
kinetics of drugs in the biomembranes after parenteral administration (35). It is well known 
that with increasing incubation time, photosensitizers (temoporfin) can migrate from the 
plasma membrane to the more sensitive stores within the cell (70).  
 
Table 3.4. Total lipid, rate constants, half lifes, and maximum percentage transferred of 
temoporfin transfer regarding total lipid content.   
Total lipid mg/ml K hr-1 t1/2 hr Max.% transferred 
1.1 0.19 ± 0.02 3.65 74.70 
11 0.28 ± 0.03 2.48 79.39 
22 0.40 ± 0.04 1.73 86.34 
Donor liposomes (DMPC/DCP/Chol.= 7:1:2) were 110 nm with PDI 0.06, Z-potential –33.4mV, and preloaded 
with 14C-temoporfin. Acceptor liposomes (POPC/Chol. = 8:2) were 115 nm with PDI 0.04 and Z-potential 
0.36mV. The ratio of donor lipid to acceptor lipid was 1:10 mg/mg. The molar drug: donor lipid ratio was 1:867.  




Figure 3.8. a) Temoporfin transfer between liposomes at three different lipid concentrations 
at 37 °C (±1). Donor liposomes (DMPC/DCP/Chol = 7:1:2) were 110 nm with PDI 0.06, Z-
potential –33.4mV, and preloaded with 14C-temoporfin. Acceptor liposomes (POPC/Chol = 
8:2) were 115 nm with PDI 0.04 and Z-potential 0.36mV. The ratio between donor and 
acceptor was 1:10. Error bars represent ± SEM for six aliquots in two experiments. b) 
Calculated total lipid content plotted versus transfer constants (see table 3.4).  
 
Previously, two different models have been suggested to explain the transfer of lipophilic or 
amphiphilic membrane components between two lipid domains (either inter-membrane 
transfer or transfer from membrane to, e.g. plasma components). The first model proposes a 
collision mechanism for, e.g. phosphatidylcholine (100) and cholesterol transfer (101). The 
second model postulates transfer through the water phase as demonstrated by cholesterol 
transfer (43, 102) and phosphatidylcholine transfer studies (43). Others claim that both 
mechanisms may simultaneously play a role, as demonstrated by the transfer of 
monoacylglycerols from SUV’s to brush border membrane vesicles (103). The kinetic 
equations describing both transfer mechanisms (through liposome collisions and through 
diffusion via the water phase) are derived in the Appendix. This derivation is based on a 
detailed distribution function of drug molecules among donor and acceptor vesicles. A similar 
derivation, although without considering the distribution of drug molecules among donor and 
acceptor liposomes, was suggested previously by Jones and Thompson (100). In both models, 
lipid transfer between liposomes through the aqueous phase via desorption from the bilayer is 
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described by a “First Order Model”. In contrast, the transfer upon the collision of liposomes 
(donor-donor, donor-acceptor, or acceptor-acceptor) corresponds to a “Second Order Model”. 
As we show in our appendix, both lead to an exponential transfer kinetics with an apparent 
rate constant K = Kd + cKc where Kd and Kc are constants and c is the total liposome 
concentration. (As we show in the appendix, there is an additional dependence of K on the 
ratio between the total number of drug molecules in the system and the maximal number of 
drug molecules that all liposomes are able to carry. This dependence is only relevant to 
liposomes with maximal, or near maximal, drug loading. For figure 3.8 the molar drug:donor 
lipid ratio was 1:867, sufficiently far away from the maximal ratio 1:10 (104). It is 
emphasized that only the collision mechanism leads to a dependence on the total liposome 
concentration c. Figure 3.8b shows the dependence of the apparent rate constant K on the total 
lipid concentration. The finite slope and finite intercept of the linear fit suggest that both the 
diffusion and collision mechanisms are involved in the transfer process.  
Comparison on the linear fit in figure 3.8b with the relation K = Kd + c Kd yields Kd = 
0.18/hr and Kc = 0.01 mL ml/(mg hr) where mL is the mass of a single liposome. The vesicles 
in this experiments have a radius of roughly R= 50 nm. Assuming a cross-sectional area a = 
0.7 nm2 per lipid, this implies a number of 
a
R2..4.2 π  = 90000 lipids per liposome (where the 
additional factor of 2 accounts for the two leaflets of the liposomal membrane). The molar 
mass per lipid is roughly 700 g/mol. Hence, mL= 700 g/mol 90000 = 10-13 mg. Kc estimation 
then becomes Kc = 0.01 mL ml/(mg hr) =10-3 μm3/hr. The liposome concentration c in K = Kd 
+ cKd can be stated conveniently in ``number of liposomes/μm3''. Here, estimation for Kd and 
Kc imply that up to a liposome concentration of c = Kd/Kc = 180/μm3 the transfer is 
dominated by the collision mechanism. In other words, once the average center-to-center 
distance between neighbouring liposomes is larger than about 200 nm, diffusion through the 
aqueous phase becomes the predominant transfer mechanism. It should be noted that the final 
estimation Kd = 0.18/hr and Kc = 10-3 μm3/hr are subject to the assumptions of underlying 
theoretical model in the appendix, namely that the mixture of mTHPC in each individual 
liposome is ideal. This neglects other possible rate limiting physical mechanisms such as 
aggregation and self-assembly of mTHPC inside the liposomes. Hence, this study suggests the 
transfer of mTHPC via both a diffusion and collision mechanism, subject to the (yet not 
verified) assumption that interactions of the drug molecules inside the liposomes do not limit 
the rate of transfer.  
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3.3.3 Effect of Temperature on [14C]mTHPC Transfer Kinetics 
The obtained results of the experiments designed to examine the sensitivity of transfer rate 
constants to temperature are presented in table 3.5 and figure 3.9. The sensitivity of the 
transfer rate on the phase transition temperature (22 °C) for DMPC can be easily seen. In the 
chosen temperature range (15-37 °C), an increase in the transfer rate constants and the 
maximum amount transferred was detected. The apparent transfer rates were 0.05 ± 0.01 hr-1, 
0.07 ± 0.01 hr-1, 0.09 ± 0.01 hr-1, 0.12 ± 0.04 hr-1, 0.17 ± 0.04 hr-1, and 0.24 ± 0.04 hr-1 while 
the plateaus reached at 24.35, 34.32, 51.50, 60.20, 70.44, and 88.41 % at 15, 19, 22, 25, 30, 
and 37 °C respectively. From the observed transfer rates it is evident that the transfer rate has 
almost doubled by increasing the temperature by 10 °C. From the van’t Hoff plot of apparent 
transfer coefficient ln KD→A versus T-1 over the temperature range 15-37 °C, the enthalpy ΔH 
was ( +96.18 KJ mol-1), the entropy ΔS (+324.17 J mol-1 K-1) and the free energy ΔG (–
4.31.KJ mol-1) could be estimated. A plot of log K over 1/T (see figure 3.9b) suggests two 
different linear regimes, separated by the main phase transition temperature (22 °C) of DMPC 
which is the major lipid in the donor liposomes. The corresponding fits to the Arrhenius 
equation yield activation energies of 56 kJ/mol below the main transition temperature and 44 
kJ/mol above the main transition temperature. The somewhat smaller activation energy in the 
fluid phase state may reflect a less severe perturbation of the lipid matrix upon transferring 
mTHPC from the hydrocarbon core of the lipid bilayer into the aqueous region outside the 
membrane. It well documented that molecular motion in general and acyl chain mobility in 
particular increases with temperature resulting in a more fluid membrane environment. 
Although a drug apparently favours a more fluid bilayer arrangement, the rate of transfer and 
the maximum amount transferred increased when the lipid membranes were heated (see table 
3.5 and figure 3.9). Moreover, the transfer rate constant of mTHPC at 37 °C is about 5-fold 
higher than at 15 °C which might lead to the rapid release of mTHPC at body temperature. 
This may be ascribed to the decrease of the hydrophobic interaction strength between the lipid 
and the drug when the temperature is increased, thus resulting in higher aqueous solubility of 
mTHPC. In agreement with the study of Wenk et al. (105) regarding paclitaxel (Taxol®) 
partitioning into lipid bilayers, the binding of paclitaxel to liposomes is four times stronger at 
20 °C than at 37 °C. In contrast, the aqueous solubility of cyclosporine A increases with 
decreasing the temperature. This might cause problems in stability-related issues of 
cyclosporine A liposomal formulations, as cyclosporine A can partition out of the liposomal 
membrane and form crystals in the suspending medium (Fahr, unpublished results). Another 
explanation for the temperature-related effects may be provided by the thermally-induced 
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changes in the conformation of the head group. It has been suggested that the N+ end of the 
phosphocholine dipole of PC, which lies parallel to the bilayer surface, becomes increasingly 
 
Table 3.5. Rate constants, have lives and maximum percent transferred of temoporfin transfer 
regarding temperature and donor vesicle’s charge.  
Temperature 
 
Donor Vesicle’s Charge 
Temp. (°C) 15°C 
 
19°C 22°C 25°C 30°C 37°C – Ve D. + Ve D. 
















t1/2 hr 13.86 
 





51.50 60.20 70.44 88.41 
 
65.31 72.29 
Donor liposomes (DMPC/DCP/Chol = 7:1:2) were 90 nm (PDI 0.08), Zeta-potential –33.4mV, and preloaded 
with temoporfin. Acceptor liposomes (POPC/Chol. = 8:2) were 115 nm (PDI 0.04) and Zeta-potential 0.36mV. 
For the comparison between oppositely charged donor liposomes (at 37°C), the negatively charged ones were 
comprised of DOPC/DCP/Chol; 7:1:2, while positively charged ones were prepared from DOPC/DOTAP/Chol 
5:3:2. Acceptor liposomes (POPC/Chol. = 8:2) were 115 nm with (PDI 0.04) and Zeta-potential -0.36mV. Donor 
lipid concentration was 1mg/mL while acceptor lipid concentration was 10mg/mL. The molar drug:donor lipid 
ratio was 1:867. The ratio between donor and acceptor was 1:50 in order to achieve sink conditions. 
 
 
Figure 3.9. a) Temoporfin transfer between liposomes at four representative temperatures 15, 
19, 22, 25, 30, and 37 °C (±1) from 3.6. Donor liposomes (DMPC/DCP/Chol = 7:1:2) were 90 
nm (PDI 0.08), Zeta-potential -33.4 mV, and preloaded with temoporfin. Acceptor liposomes 
(POPC/Chol = 8:2) were 115 nm (PDI 0.04) and Zeta-potential -0.36mV. Error bars represent 
± SEM (n=9). The molar drug:donor lipid ratio was 1:867. b) Arrhenius plot of all 
temperature points from table 3.6 and stepwise fit to the Arrhenius equation.  
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submerged in the hydrocarbon chain with increasing temperature, which results in lateral head 
group repulsion and decreasing surface pressure. The reduction of surface pressure may be 
expected to favour transfer (106). Another possible explanation for these temperature related 
effects may be found by thermodynamic considerations. When the temperature increases the 
enthalpy of transfer becomes more positive and the free energy of transfer less favourable 
which in turn enhances the water solubility of hydrophobic solutes like mTHPC. 
Counterbalancing this effect the incorporation of non-polar molecules like mTHPC across and 
into interfacial membrane bilayer is thought to be the result of the hydrophobic effect, which, 
in turn, is driven by entropic factors (107). The positive entropy of solutions which promotes 
drug transfer from aqueous phase into hydrophobic domains, is believed to result from the 
dissolution of an ordered water shell around the drug (108). In the present study, the positive 
value of the enthalpy (ΔH = +96.18 kJ mol-1) may increase the release of mTHPC from donor 
lipid phase to the aqueous phase. After that, the positive entropy (ΔS = +324.17 J mol-1 K-1) 
of the solution promotes mTHPC to be transferred into the acceptor since the acceptor lipid to 
donor lipid is 10:1 mg/mg. It could be concluded from the positive values of entropy a ΔS and 
the negative value of the free energy ΔG that mTHPC transfer over the temperature range of 
15-37 °C is entropically dominated. It is interesting also to discuss the prediction of a kinetic 
model, presented in the appendix, for the free energy of transfer ΔG (see equation 2-10). To 
this end, it should be noted from the model in the appendix that the model assumes all 
liposomes to be equivalent (i.e. mTHPC is assumed to have the same standard chemical 
potential in donor and acceptor vesicles). The enthalpic contribution ΔH to ΔG therefore 
vanishes. On the other hand, the equilibrium constant KD->A = Na/Nd is given in our model by 
the ratio of the numbers of acceptor to donor liposomes. Then, with equations 4 and 5 and 
using the experimentally fixed ratio Na/Nd = 10 (see table 3.5), we find ΔG = –RT ln (Na/Nd) 
= –5.7 kJ/mol, which is in reasonable agreement with the experimentally determined value 
ΔG = –4.31 kJ/mol. Although these experiments reveal the presence of an enthalpic 
contribution to ΔG, the transfer is dominated by entropy. This provides a major justification 
for the assumption of constant standard chemical potential in the kinetic model.  
 
3.3.4 Effect of Donor Liposome’s Charge on [14C]mTHPC Transfer Kinetics 
To investigate the role of donor liposome charge on the mTHPC transfer rate, we used binary 
lipid mixtures as compiled in table 3.5. These mixtures are composed of DOPC either with 
DOTAP or with DCP to prepare positively and negatively charged vesicles, respectively. 
From table 3.5 and figure 3.10 we conclude, that positively charged liposomes exhibit faster 
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transfer rates than negatively charged liposomes. The observed transfer rate of positively 
charged vesicles (0.43 ± 0.06 hr-1) was about 1.7-fold of the negatively charged ones (0.26 ± 
0.03 hr-1). A possible reason for this finding may be related to the influence of charged lipids 
on physical membrane properties. Binary anionic/zwitterionic and cationic/zwitterionic lipid 
mixtures exhibit characteristic differences in terms of their average cross-sectional area per 
lipid, head group orientation, and interaction strengths as evidenced by experiments (109-
111), Molecular Dynamics simulations (112), and mean-field electrostatic modelling (113, 
114). Generally, cationic lipids tend to electrostatically interact more strongly with 
zwitterionic lipids due to the typically close proximity of the cationic charge to the phosphate 
group of the zwitterionic lipid. Hence, mixed cationic/zwitterionic membranes are more 
condensed than their anionic counterparts, which suggest a less favourable packing 
environment of drug molecules inside the membrane and a larger driving force for the transfer 
out of the membrane interior. In terms of the maximum amount transferred, there is no 
significant difference between the both as 65.31 % and 72.29 % for negatively and positively 
charged liposomes were transferred, respectively.  
 
3.3.5 Effect of Donor Lipid Saturation and Acyl Chain Length on [14C]mTHPC Transfer 
Kinetics 
The effect of degree of saturation of lipid used in donor vesicles is presented in table 3.6 and 
figure 3.11. It is evident that there is no significant difference between transfer rate constants 
0.26 and 0.18 hr-1 of DOPC (18:1/18:1, Tm = –20) and SOPC (18:0/18:1, Tm = +6) 
respectively. While for DSPC (18:0/18:0, Tm = +55) was about 4-fold of each (1.00 hr-1). 
Since membrane rigidity is increased with increasing the degree of hydrocarbon saturation, a 
potential relationship between transfer rate and rigidity was evident. The maximum amount 
transfer percents were 65.31, 83.63, and 82.01 for DOPC, SOPC, and DSPC respectively. As 
an extension of the former experiment, the influence of fatty acyl chain length was examined. 
With the four di-saturated phospholipids used [(DMPC 14:0/14:0, Tm = +22 °C), (DPPC 
16:0/16:0, Tm = +41 °C), (DSPC 18:0/18:0, Tm = +55 °C), and (DBHPC 22:0/22:0, Tm = 
+75 °) the transfer rate was faster for the phospholipid having longer length at 37 °C which 
was either below or above their respective phase transition temperatures (table 3.6 and figure 
3.12). It is obvious that there is no significant difference between the transfer rate of DMPC 
(0.28 ± 0.03 hr-1) and DPPC (0.35 ± 0.03 hr-1). The transfer rate constants for DSPC and 
DBHPC increased to about 4-fold (1.00 ± 0.11 hr-1 and 1.24 ± 0.30 hr-1 respectively). The 
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maximum amount transferred was almost the same as the plateaus were reached at 79 %, 86 
















Figure 3.10. Temoporfin transfer between negatively and positively charged donor and 
neutral acceptor liposomes at 37 °C (± 1 °C). Donor liposomes formulated as 
(DOPC/DCP/Chol.= 7:1:2) and (DOPC/DOTAP/Chol = 5:3:2 loaded with temoporfin. 
Acceptor liposomes (POPC/Chol = 8:2) were 115 nm (PDI 0.04) and Zeta-potential -0.36mV. 
The ratio between donor and acceptor was 1:10. Error bars represent ± SEM (n = 6). The 
molar drug:donor lipid ratio was 1:867.  
 
The overall affinity of the porphyrin for the vesicles is largely dominated by hydrophobic 
interactions between the macrocycle core and the phospholipid chains. Two of the chain's 
characteristic factors are the unsaturation and acyl chain length. A sharp increment in mTHPC 
transfer rates was shown only by using DSPC (Tm = +55 °C) and DBHPC (Tm = +75 °C). 
Below the phase transition temperature a potential relationship between transfer rate and 
rigidity is evident. As presented in table 3.6 and figures 3.12b, there is no significant 
difference between transfer rate constants for DOPC (Tm = -20 °C), SOPC (Tm = +6 °C), 
DMPC (Tm = +22 °C), and DPPC (Tm = +41 °C), whereas for DSPC (Tm = +55 °C) and 
DBHPC (Tm = +75 °C), the transfer rate was increased by about a factor of 4. The 
experiments were conducted at a temperature of 37 °C at which DOPC, SOPC, and DMPC 
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reside in the fluid phase state whereas DPPC tends to form the “ripple” phase. In contrast, 
membranes containing DSPC and DBHPC exhibit the gel phase, where the fully stretched and 
well packed fatty acyl chains give rise to more rigid membrane architecture. This could cause 
the drug molecules to be squeezed out of the bilayer interior and to accumulate near the 
liposome surface (35). This would increase the probability of being transferred to another 
membrane, as desorption of the drug from the liposomes becomes easier. A rapid release of a 
hydrophobic drug (Vitamin A) was also observed for solid lipid nanoparticles (115), the 
classic example of a rigid lipidic matrix. It was shown for these rigid carriers (116), see also 
the review in reference (117), that the mere lipophilicity of carrier and drug does not 
necessarily cause a retardation effect. Only if there is a structural fit between carrier assembly 
and drug is a retardation effect to be expected (117). For less rigid carriers such as liposomes 
in their fluid state, the structural fit may be provided by the ability of the fluid-like lipid tails 
to adapt to the shape of the hydrophobic drug molecule. Such accommodation would be 
expected to be weakly dependent on chain length, as is observed. However, this effect is 
overridden by the rigidity of the membrane, as exemplified by the case of DBHPC. Maman 
and Brault (118) report, that varying the bilayer thickness by using C14-C22 unsaturated 
phospholipids at pH 6.5, a profound decrement in dicarboxylic porphyrin transfer rate was 
observed. They ascribed this influence to the length of the hydrocarbon chain since all of 
unsaturated lipids used in their report are liquid at their experimental temperature 25 °C, 
thereby the degree of burying porphyrin within the bilayer will be high. In a study of 
anticancer teniposide partitioning into membranes using different lipids regarding 
unsaturation and acyl chain length at 37 °C, Stephan and co-workers found that the 
partitioning coefficient was decreased when the membrane rigidity increased having the 
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Table 3.6. Phase transition temperatures, Z-averages, rate constants, half lifes and maximum 
percent transferred of temoporfin transfer regarding donor lipid saturation and donor lipid 
acyl chain length at 37 oC. 
 Unsaturation 
 
Acyl chain length 
Lipid  DOPC SOPC DSPC DMPC DPPC DSPC DBHPC 
Tm (oC) -20 +6 +55 +22 +41 +55 +75 



















2.67 3.85 0.69 2.48 1.98 0.69 0.56 
Max. % 
transferred 
65.31 83.63 82.01 79.39 86.38 82.01 75.51 
Donor liposomes (PhL/DCP/Chol.= 7:1:2) preloaded with temoporfin had PDIs less than 0.10. Acceptor 
liposomes (POPC/Chol. = 8:2) were 115 nm (PDI 0.04) and Zeta-potential -0.36mV. The donor lipid 





































Figure 3.11. Temoporfin transfer between liposomal membranes regarding hydrocarbon 
chain saturation (DOPC, SOPC, and DSPC) at 37 oC (±1). Donor liposomes formulated as 
(PhL/DCP/Chol = 7:1:2) and loaded with 14C-temoporfin. Acceptor liposomes (POPC/Chol = 
8:2) were 115 nm with PDI 0.04 and Z-potential 0.36mV. The ratio between donor and 
acceptor was 1:10. Error bars represent ± SEM for six aliquots in two experiments for DOPC 



































































Figure 3.12. a) Temoporfin transfer between liposomal membranes regarding carbon chain 
length (DMPC, DPPC, DSPC, and DBHPC) at 37 oC (±1). Donor liposomes formulated as 
(PhL/DCP/Chol = 7:1:2) and loaded with 14C-temoporfin. Acceptor liposomes (POPC/Chol = 
8:2) were 114.8nm with PDI 0.04 and Z-potential 0.36mV. The ratio between donor and 
acceptor was 1:10. Error bars represent ± SEM for six aliquots in two experiments for DMPC 
and DPPC while for DSPC and DBHPC nine aliquots in three experiments. b) Rate constants 
as a function of the phase transition temperature of the donor liposome of six different 
phospholipids regarding saturation and fatty acyl chain length (Data taken from table 3.7).  
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4.1 Immobilized Artificial Membrane (IAM.PC.DD2) 
The retention behaviour of a set of neutral and positively or negatively charged solutes on the 
IAM.PC.DD2 stationary phase was compared to traditional lipophilicity index log Poct. 
Significant correlations were found between the retention factor log kwIAM on this stationary 
phase and log Poct or log D7.0 for neutral or structurally related compounds, implying that the 
retention mechanisms are the same for neutral or structurally related compounds. The 
retention of the ionized compounds on the IAM.PC.DD2 is controlled not only by 
lipophilicity but also by extra interactions, mainly electrostatic interactions between charged 
solutes and phospholipids. For the solutes investigated in this study, positively charged 
compounds are more retained than negatively charged solutes. The ranking order of retention 
strength is: β-blockers > (4-methylbenzyl) alkylamines > NSAIDs > monofunctional 
carboxylic acids. This implies that the interaction between positively charged solutes and the 
phosphatidylcholine-based IAM stationary phase is larger than that between negatively 
charged solutes and the membrane, and that the electrostatic interaction depends on the 
structural characteristics of the solutes investigated. 
 
4.2 XBridgeTM Shield RP18 Stationary Phase 
Using a wide range of structurally diverse neutral, acidic, ampholytic and basic solutes 
(including drugs) and eluents enriched in 1-octanol, the XbridgeTM shield RP18 phase yielded 
a lipophilicity index log Kw highly correlated with log Poct values. An LSERs analysis showed 
that retention on the XbridgeTM shield RP18 phase and partitioning in 1-octanol/ water are 
controlled by the same balance of structural properties, namely Van der Waals volume (Vw), 
H-bond acceptor basicity (β) and dipolarity/polarizability (π*). The study showed that this 
novel stationary phase overcomes the shortcomings of the silica-based stationary phases, 
whose application in lipophilicity measurements is limited to neutral and acidic compounds. 
The results of this study are of potential interest for the high-throughput screening of 
lipophilicity in drug discovery, where basic compounds predominate. 
 
4.3 Temoporfin (mTHPC) Transfer between Liposomal Membranes 
The kinetics of transfer of the hydrophobic drug temoporfin from donor to acceptor liposomes 
was discussed. The results showed that the transfer rates depend not only on thermodynamic 
parameters such as temperature and concentrations of donor and acceptor vesicles, but also 
characterize it in terms of liposomal material properties. The observed transfer kinetics 
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generally follows a simple exponential behaviour with a corresponding rate constant that 
contains information about the mechanism of transfer. A theoretical model that analyzes the 
transfer based on a detailed distribution function of drug molecules in liposomes was 
presented. The model accounts for drug transfer through liposome collisions and via diffusion 
through the aqueous phase. Comparison of the theoretically predicted with the measured rate 
constants suggests that both mechanisms contribute to the transfer. The collision mechanism 
dominates for large overall liposome concentration (larger than about 1/(200 nm)3). The 
model gives also reasonable agreement for the (entropy-dominated) free energy of transfer of 
























































This appendix describes a kinetic model that predicts an exponential transfer curve and 
includes both a diffusion-based and a collision-based transfer mechanism. The model is 
microscopic in the sense that it explicitly accounts for the distribution of [14C]mTHPC in 
donor and acceptor liposomes. Specifically, we introduce the numbers d =dj(t) and aj=aj(t) of, 
respectively, donor and acceptor liposomes that contain j molecules of [14C]mTHPC. The 
index j varies in the region 0 ≤ j ≤ where m is the maximal number of mTHPC that can be 











 are both conserved. All N=Nd+Na 











 of mTHPC residing in, respectively, donor and acceptor 
vesicles are not conserved, but the sum M=Md+Ma is. A simple kinetic model of [14C]mTHPC 
transfer among all different donor and acceptor vesicles can be written as 
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  [5-1] 
 
This model accounts for two different transfer mechanisms, transfer upon collisions between 
vesicles and transfer through diffusion via the aqueous phase. The collision and diffusion 
mechanisms are accounted for by the first and second lines, respectively, in the expressions 
for the time derivatives of dj and aj. Specifically, the first line accounts for all possible 
collisions that increase (terms with positive sign) or decrease (terms with positive sign) the 
number dj (and analogous for aj). Each term is proportional to the concentration difference of 
[14C]mTHPC between the colliding vesicles. The rate constant K for transfer through 
collisions is assumed to be constant, irrespective of the nature of the collision (donor-donor, 
acceptor-acceptor, or donor-acceptor). The second line describes a diffusive transport through 
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the aqueous phase; Kd is the rate constant for the transfer of a single [14C]mTHPC from a 
vesicle into the aqueous phase or vice versa. Note that the set of equations (1) treat all 
liposomes to be structurally and chemically equivalent; i.e. with donor and acceptor 
liposomes to have the same equilibrium concentration of [14C]mTHPC. Moreover, equations 
(1) assume that due to its low solubility [14C]mTHPC is present in the aqueous phase with 
negligible concentration. 
Equations (1) can be expressed as kinetic equations in terms of Md=Md (t) and Ma=Ma(t) only. 






−=  [5-2] 
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The set of equations (1) effectively describes the reversible chemical reaction D⇌A of 
[14C]mTHPC bound to donor (D) and acceptor (A) liposomes, with identical on and off rate 
constants KNd/N and KNa/N, respectively. The kinetics of this net reaction strictly follows 
first-order kinetics, despite the fact that the transfer via liposome collisions is based on a 
bimolecular reaction, namely the collision between two liposomes. However, the number of 
liposomes does not change with time, leaving the rate of collisions between liposomes 
constant. This absence of a depletion of the reactants renders the transfer first order. The 
present model predicts an equilibrium constant, defined in equation 2, of KD→A = Na/Nd. With 
the initial conditions Md(t = 0)=M and Ma(t = 0)= 0 the predicted time dependence is given by 
a simple exponential function 
 






tM −−=−= 11         [5-4] 
where Na/N is the fraction of acceptor liposomes in the system. Equations (3) and (4) 
represent an exact solution of the model introduces through equations (1). Clearly, there are 
two different regimes, corresponding to diffusion-dominated ((N −M/m)/V << Kc/Kd) and 
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collision-dominated ((N −M/m)/V >> Kc/Kd) transport. The observed time dependence for the 
[14C]mTHPC transfer from donors to acceptors does not depend on the overall concentration 
of liposomes in the diffusion-dominated regime. In the collision-dominated regime the 
transfer becomes faster with increasing liposome concentration. On the other hand, a 
dependence of K on total number of drug molecules, M, is only encountered in the diffusion-
dominated regime. Here, K increases with M. If all donor liposomes initially contain their 
maximal amount of drug molecules then M = mNd. Here again is pointing at the simplistic 
level of the present model. First, it does not account for the chemical specificity of the donor 
and acceptor liposomes. That is, the chemical potential of drug molecules is the same in 
donors and acceptors. Consequently, in equilibrium all individual liposomes (donor and 
acceptor liposomes) carry the same number of drug molecules (as expressed by KD→A=Na/Nd), 
and there is no enthalpic contribution to the free energy of transfer ΔG; see equation [2-10]. 
Second, our model does not account for nonideal mixing of drug molecules in liposomes, 
including possible aggregation phenomena or self-assembly. Including the difference in 
affinity for drug molecules of donors and acceptors as well as aggregation of drug molecules 
within liposomes will be the subject of future theoretical work. This model was established 
with the help of Prof. Dr. Sylvio May (Department of Physics, North Dakota State University, 
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